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Abstract 
 
Epidermal Growth Factor (EGF) and Transforming growth factor (TGFβ1) promotes 
EMT in primary prostate cancer cells via Ras signaling. Inhibitory effects of EGCG on 
EMT induced matrix metalloproteinase (MMP) activity in prostate cancer cells. 
Devika Varma 
Mark E. Stearns, Ph.D. 
 
 
 
 
Epithelial to mesenchymal transition (EMT) may be a critical step in prostate 
cancer progression and metastasis.  However, we do not understand the ligands and 
conditions controlling EMT.  We have examined the factors controlling EMT in primary 
prostate cell lines isolated from human prostate cancer (i.e. IBC-10a and PCa-20a cells).  
We have shown that a combination of EGF and TGFβ1 (E+T) can promote expression of 
Vimentin and matrix metalloproteinases (MMP2 and MMP9) during induction of EMT in 
the primary cell lines.  We have found that an intact Ras signaling was essential for E+T 
induced EMT.  We have stably transfected IBC-10a cells with pBABE.ras constructs 
containing three distinct Ras mutations (i.e. C40, G37 and S35).  In cells transfected with 
C40 and S35, TGFβ1 alone induced MMP2 and MMP9 secretion, whereas, E+T was 
essential to induce MMP2 and MMP9 secretion in G37 transfected cells (i.e. which 
activates RalGDS and blocks Akt-1 and MEK signaling).  Taken together, the data have 
shown, for the first time, that E+T activation of Akt-1 and MEK signaling pathways play 
a key role in EMT.  One added goal of the study was to identify potential therapeutic 
agents which can block EMT.  We have found that the green tea extract, 
Epigallocatechin-3-gallate (EGCG), blocks E+T induced MMP secretion in a dosage 
  
xi 
dependent manner in both the primary cell lines and malignant PC3ML2 tumor cells.  In 
sum, our work has demonstrated that specific ligands regulate EMT and that a herbal tea 
extract has potential therapeutic benefit in blocking ligand dependent EMT.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
13 
Chapter 1. Introduction 
Prostate Anatomy and Physiology 
 
The prostate is a tubuloalveolar gland of the male reproductive system that lies 
between the bladder and the rectum in males (Figure 1). The main function of this gland 
is to produce the prostatic fluid, an important component of the semen, which contains 
several proteins vital for the survival and function of sperms. (Hayward et al, 2000) It is 
composed of pseudostratified columnar epithelium with basal nuclei lining the ducts. The 
epithelial basement membrane is further bordered by basal epithelial cells. This 
epithelium is surrounded by a fibromuscular stroma. (Hayward and Cunha, 2000) 
The main function of the prostate is to assist the seminal vesicles in the 
production of the ejaculate which is primarily composed of proteins that have a variety of 
functions like coating and uncoating of the spermatozoa and others like prostate specific 
antigen (PSA). The PSA is produced by the columnar epithelial cells of the prostate and 
secreted into the prostate ducts. (Hayward and Cunha, 2000) 
 
 
Figure 1: The location of the prostate gland. The prostate gland lies between the bladder 
and the rectum in males.3 
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Prostate Cancer Statistics 
 
With an estimated mortality of close to 27,000 in 2009, prostate cancer is the 
leading form of cancer in the United States excluding skin cancer. This cancer has been 
found to affect older men who are 55 years or older. According to the National Cancer 
Institute, the median age at death was 80 in the United States between 2002 and 2006. 5 
Prostate Cancer Stages 
 
 
 
Figure 2: Stages in prostate cancer. The above figure shows the four stages in prostate 
cancer. (Adapted from National Cancer Institute, 2005) 
 
Cancer stages are often represented by the Gleason’s coefficient which is a score 
from 2-10, describing how metastatic the cancer cells are compared to normal cells. The 
higher numbers are associated with a higher degree of metastasis as represented by the 
figure above. Metastasis in prostate cancer usually involves the spread of the cancer into 
surrounding organs like the bladder, rectum, bone, liver or lungs. [1] 
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Prostate Cancer Treatment 
 
Several methods are presently being used to identify and treat prostate cancer. 
The main concern lies in the early detection of the disease to prevent metastasis. The PSA 
test is the most common diagnostic test, though it is currently found to be inefficient in 
detecting budding tumors in the prostate. The detection of the PCA3 gene in urine is a 
newer method used for diagnosis and has been found to be more reliable. Other ways rely 
on imaging techniques like Color Doppler Ultrasound, enhanced MRI and CT. [1, 2] 
Treatments currently employed for prostate cancer primarily include surgery, 
radiation therapy, high intensity focused ultrasound, hormone therapy, chemotherapy, 
vaccines and antibodies. Radiation therapies that entail conformal radiation therapy 
(CRT), intensity modulated radiation therapy (IMRT), and proton beam radiation have 
been found to be more localized preventing damage to the surrounding normal tissue. [2] 
Epithelial to Mesenchymal Transition 
 
The epithelial to mesenchymal transition (EMT) is a critical event in promoting 
the invasive capacity of malignant cells. There are several factors that have been found to 
transform tumor cells from its epithelial phenotype to a mesenchymal phenotype. These 
include ligands and signaling pathways like transforming growth factor β (TGFβ) and 
RTK/Ras signaling, Wnt, Notch, Hedgehog signaling pathways. Repression of genes 
governing an epithelial phenotype like E- cadherin by transcription factors like Snail or 
Slug is another means of transforming epithelial cells to a mesenchymal phenotype. 
(Huber et al, 2005) It is usually a combination of the above stated factors that helps 
induce EMT in reality. Unlike epithelial cells, which form tightly packed layers around 
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organs, mesenchymal cells do not adhere to each other tightly and form the inner layers 
of organs. Epithelial cells tend to migrate when grown in vitro and have a fibroblast and 
spindle shaped morphology. (Lee et al, 2006) The ability of malignant epithelial cells to 
acquire invasive properties requires the loss of cell junctions and the gain of 
mesenchymal features such as the spindle- shaped morphology. The loss of E-cadherin 
and β catenin is required for this process to occur. (Lee et al, 2006) Characteristically, the 
EMT process is marked by the loss of E- cadherin and the increased levels of 
mesenchymal markers like Vimentin, Fibronectin, Snail, Slug, and Twist. Snail and Slug 
are the first transcription factors that were found to regulate the EMT and cell motility. 
(Barralo et al, 2005; Bolos et al, 2003; Cano et al, 2000; Comijn et al, 2001) Although 
EMT is a common event in vivo, the acquisition of this state in cells in vitro has been 
reported to be a rare event in a study by Moses and colleagues which showed that only a 
few murine cell lines were able to complete the epithelial to mesenchymal transition out 
of the 18 cell lines they tested using TGFβ (Brown et al, 2003). The transient reversible 
nature of EMT makes it difficult to observe this phenomenon in human cell lines, 
especially in primary cancer cell lines, where only a selective population of cells 
undergoes permanent EMT (Yang et al, 2006). A study in androgen refractory prostate  
cancer cells showed that soluble factors like EGF and TGFβ can increase bone turnover 
in these cells marked by the high expression of (Receptor Activator of NF-KB Ligand) 
RANKL, a marker indicated in prostate bone metastasis (Zhau et al, 2008). 
Two zinc finger transcription factors called ZEB1 and ZEB2 are also implicated 
in regulating EMT by repression of E- cadherin. They function by binding to the 
promoter regions of E- cadherin and repressing its expression.  (Comijn et al, 2001) EMT 
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is characterized by signals released from the tumor stroma like TGF, HGF, EGF, and 
PDGF leading to the activation of several transcriptional factors like Snail, Slug, zinc 
finger E-box binding homeobox 1 (ZEB1), Twist, Goosecoid, and FOXC2. The above 
transcriptional activation induces the activation of intracellular factors like ERK, MAPK, 
PI3K, Akt, Smads, RhoB, lymphoid enhancer binding factor (LEF), Ras, and c-Fos along 
with proteins such as β4 integrins, α5-β1 integrin, and αV-β6 integrin, which are 
important components of the cell surface. (Kalluri and Weinberg, 2009) 
 
 
Figure 3: Steps involved in EMT. The above figure illustrates the different steps involved in 
the EMT process. The induction of a mesenchymal phenotype involves the expression of 
several genes like Slug, Snail, Vimentin, β catenin and several others. (Figure adapted from 
Kalluri and Weinberg, 2009). 
 
Matrix metalloproteinases 
 
Effective metastasis requires the degradation of the basement membrane of the 
primary tumor. Matrix metalloproteinases (MMPs) are endoproteins that have the ability 
to cleave several ECM components and are involved in matrix degradation processes 
during development as well as tumor invasion.  Approximately 22 different MMPs have 
been reported, and depending on the substrate specificity have been reported to degrade 
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ECM components like collagen, fibronectin and laminins. These enzymes have two 
functional domains; a catalytic domain that consists of a Zn2+ binding site and COOH 
terminal domain that determines substrate specificity. The terminal domain, also called 
the hinge region is suggested to contain a Ca2+ binding site. A glutamine and aspartame 
rich region is conserved in all MMPs between the Zn2+ binding site and the hinge region.  
These enzymes remain inactive when a “pro” domain is attached to them and the catalytic 
activity is maintained by the “catalytic” domain. MMP2 and MMP9 have been known to 
degrade Type IV collagen. MMP2 resides in the ECM bound to gelatin, laminin and Type 
I and IV collagen. Both MMP2/9 are of particular interest in case of tumor metastasis as 
they are found bordering the epithelial and mesenchymal junction. It has also been shown 
that MMP2 is required for the activation of proMMP9. (Toth et al, 2003; Birkedal- 
Hansen, 1993)  
 
Figure 4: Prototype structure of a generic MMP. The above figure shows the main 
components that make up MMPs. The most important parts of this enzyme are its catalytic 
domain and the hinge like region. (Figure adapted from Birkedal- Hansen, 1993) 
 
The proMMPs need to be cleaved by soluble factors or other proteases to be able to 
release the active forms. MMP3/ Stromelysin has been found to be the activator of 
proMMP9 and it cleaves the zymogen at the Glu-Met bond creating a transitional 86kDa 
protein. Further cleavage by MMP3 at the Arg-Phe bond results in the active MMP9 of 
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82kDa. (Ogata et al, 1991) The plasmin system also plays a role in creating active MMP 
forms by cleaving the pro forms at the right sites. Similarly, proMMP2 gets activated by 
the co-ordination between TIMP-2 and MMP14 (MT-MMP1) (Hernandez-Barrantes et 
al, 2000). 
Growth factors and signaling 
 
TGFβ one of the earliest growth factors recognized to play a prominent role in 
cancer progression and EMT. TGFβ1 has been found to play a dual role in cancer 
progression and metastasis. In the initial progression of cancer TGFβ1 has been found to 
act like a tumor suppressor but in the latter stages, especially during metastasis it has 
been found to accentuate the process. (Bierie and Moses, 2006) In non cancerous cells, 
TGFβ1 is a cell proliferation inhibitor and performs this function by inducing the 
expression of cyclin kinase inhibitors like p15IKN4a, p21K1PI25 and p27K1PI29 through the 
Smad pathway. However, this ligand has found to stimulate proliferation in many cancer 
cells like those obtained from the colon, pancreas and the prostate. Binding of TGFβ1 
with its type two receptor leads to the receptor interaction with occludin and is followed 
by the phosphorylation of Par6 protein. This step leads to the recruitment of Smurf1 
which results in the degradation of Rho- a step is primarily responsible for the loss of 
polarity in epithelial cells. TGFβ1 also alters the gene expression of desmosomal proteins 
responsible for cell- cell adhesion by activating Slug. (Tsuji et al, 2009) TGFβ1has been 
found to regulate invasive properties of cancer cells and reduce their adhesive properties 
by decreasing levels of E- cadherin. It does so by inducing E-cadherin repressors like 
Twist1/2, ZEB1/2, Snail1/2, FOXC2 and Goosecoid that bind to the CCH1 promoter 
region of E- cadherin gene. (Tsuji et al, 2009)  In case of normal cells, this ligand 
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increases the formation of the extracellular matrix, but in invasive tumors it has been 
found to increase protease levels.  
The epidermal growth factor (EGF) primarily functions as activator for the 
receptor EGFR tyrosine kinase. It primarily assists the proliferation of epidermal and 
epithelial tissues and influences some other cell types in vivo. (Carpenter and Cohen, 
1979)  It plays a major role in the downstream signaling of the PI3K/ AKT pathway and 
the p42/44 MAPK pathway. Some studies in the past have suggested the role of EGF in 
increasing the invasive capacity of non neoplastic and neoplastic cells. (Lund et al, 1990) 
The tumor stroma often has higher levels of EGF compared to healthy tissue and is 
associated with inflammatory mechanisms at least in pancreatic cancer. (Farrow et al, 
2004) Significant number of studies has associated an increase of MMPs in tumors with 
EGF and its pathways. In particular, the PI3K pathway is prominently associated with the 
invasive and migratory effects of EGF via NF-KB and thus indirectly affects MMP 
production. These results suggested in breast cell lines line up with results of other 
tumors like that of ovarian and pancreatic origins. (Moulik et al, 2008; Ellerbroek et al, 
2001) Interestingly, studies with glioblastoma cells that compared the effects of EGF on 
migration and invasiveness in 2D versus 3D showed that cells grown in 3D displayed a 
high directional persistence (dependence on matrix dependence and protease activity) 
when compared to a 2D culture that showed a decrease in directional persistence. This 
suggests that cell intrinsic factors resulting in migration and invasion are overridden by 
EGF induced cell extrinsic factors that reduce matrix steric hindrance. (Kim et al, 2008)  
A new role of EGFR, independent of its tyrosine kinase activity was recently discovered. 
It has been found that EGFR directly plays a role in promoting and stabilizing the 
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Na/Glucose co- transporter and thus facilitating the uptake of glucose in cancer cells. 
(Engelman et al, 2008) Although some past studies have shown the sole effect of EGF in 
the promotion of migration and invasion in cancers, these effects are found to magnify 
drastically in the presence of TGFβ1. (Wilkins-Port et al, 2009)  
Ras and its pathways 
 
The Ras protein is found in the inner plasma membrane and its activity is 
regulated by alternating between the GDP bound inactive form and the GTP bound active 
forms. Active Ras has a number of effector molecules like PI3K, Ral, Raf and Tiam1. 
There is usually an over expression of tyrosine kinases in cancers, particularly of the EGF 
family which is found to cause a constant activation of Ras even when Ras mutations are 
absent. 
One of most studied Ras effectors are the Raf serine/ threonine kinases. Activated 
Raf further activates MEK1/2 which are kinases for ERK1/2 MAPKs. The activated 
MAPK regulates gene expression when translocated into the nucleus. When tested in 
nude mice, Ras transformed cells with a Raf mutation exhibited lung metastasis which is 
linked to the activation of MEK by Mos, it’s ectopic activator.(Posada et al, 1993) The 
phospoinositide 3-kinase (PI3K) is another important and well studied effector of Ras. 
Besides its well known role in increasing cell motility and alteration of cell- ECM 
interaction, it has also shown to regulate tumor cell metastasis by enabling tumor cells to 
escape 'matrix deprivation- induced apoptosis or anoikis. (Frisch et al, 1997) The 
activation of Rac GEFs (Guanine Exchange Factors) by PI3K leads to the increase in cell 
motility as Rac is responsible for actin reorganization and 'membrane ruffling'. (Etienne-
Manneville and Hall, 2002) A recent addition to the list of Ras effectors is Tiam1, a 
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protein initially identified as T-lymphoma invasion and metastasis protein (Tiam1). This 
protein has been suggested to work in conjunction with Rac as its GEF. Several Tiam 1 
knockout studies in mice resulted in drastic reduction of Rac expression suggesting the 
correlation between the two proteins. (Malliri et al, 2002) 
Interestingly, the Met proto-oncogene plays a major role in tumor metastasis and 
is particularly found up regulated in tumor metastases. H-Ras transformed fibroblasts and 
epithelial cells express much higher levels of the Met receptor along with higher 
migration capabilities. (Webb et al, 1998)  
Ras is the major regulator of most of the above mentioned tumor promoting 
actions, although the Ras pathways involved in each of these steps varies from one cell 
type to another. These pathways work in conjunction in areas like regulation of the actin 
filaments, ECM degradation, reduced cell adhesion and angiogenesis. (Campbell et al, 
2004) Overall, Ras plays a very important role in tumor progression and is evidently 
involved in many routes leading to tumor metastasis. Ras effector pathways like ERK and 
Akt are well established to play a role in prostate cancer progression (Gioeli et al, 1999). 
One of the most recent findings about Ras signaling in prostate cancer suggests a co-
operation between Ras and NF-KB to promote tumor growth and metastasis. Data 
suggests that the epigenetic suppression of a RasGAP gene called DAB2IP is required for 
NF-KB activation in prostate cancer cells leading to prostate metastasis. (Min et al, 2010) 
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Figure 5:  Important Ras pathways involved in cancer. The above image summarizes the 
activation of Ras with GTP binding and also shows the different effectors of Ras that 
further decide the fate of the cell’s with respect to its invasive capabilities. Raf, PI3K, Tiam1 
and RalGEF are the main effectors of Ras. (Figure adapted from Campbell et al, 2004) 
 
Epigallocatechin-3-gallate 
 
 Innumerable cancer treatment methods have been proposed and currently 
several of them are being used in clinics. Antioxidants have been a major target for 
cancer treatments because of their ability to negate the carcinogenic effects of reactive 
oxygen species. Epigallocatechin-3-gallate (EGCG), an important flavanol in green tea, is 
an antioxidant and therefore has recently been proposed to be used in combination with 
other cancer drugs. (Fujiki et al, 2002) The chemopreventive activity of this molecule 
depicted by its ability to inhibit invasion and angiogenesis makes it useful for further 
investigation in the research for cancer treatment. The catechins and polyphenols found 
in green tea are the main components that provide this anti-carcinogenic effect. (Paschka 
et al, 1998) Particularly, EGCG’s effect on growth inhibition of tumor cells along with its 
effects on invasion and migration of tumor cells have been studied in some areas of 
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cancer. For example, studies on prostate cancer have shown clear indication of apoptosis 
and growth inhibition in these cells where nuclear fragmentation and chromatin 
condensation was typical in the EGCG treated cells. (Paschka et al, 1998, Hastak el at, 
2003) Inhibitory effects of EGCG in several signal transduction pathways have been 
proposed like the p38, JNK and ERK pathways (Katiyar et al, 2001). Studies have also 
shown that EGCG prevents the binding of EGF to EGFR, preventing the induction of 
several EGF pathways including Ras associated ones (Masuda et al, 2001; Masuda et al, 
2002). Due to its inhibitory effects on AP-1 along with its direct effects, EGCG plays a 
very important role in suppressing MMP activity and production (Dong et al, 1997).   
Chapter 2. Materials and Methods 
Cell Cultures 
 
The IBC-10a cell strain was isolated from the right peripheral zone of a prostate 
gland with Gleason score 6 tumors.  Cells were immortalized by LXSN-hTERT retroviral 
transfection (courtesy of John Rhim, Center for Prostate Disease Research, USUHS, 
Bethesda, MD) using methods previously described (Miki et al, 2007). IBC-10a cells 
were found to express CK5, CK18, p63 and PTEN and have been categorized as 
intermediate basal cells (Goodyear et al, 2009). Cells were maintained in serum free 
complete keratinocytes media (cKm) containing EGF, pituitary extract and 1% penicillin/ 
streptomycin (Invitrogen Inc., Carlsbad, CA). PCa-20a cells were isolated from human 
Gleason score 7 prostate tumors. They were found to express CK5, CK18, p63 and PTEN 
and have been categorized as intermediate basal cells (unpublished data). Cells were 
maintained in serum free complete keratinocytes media (cKm) which contains EGF, 
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pituitary extract and 1% penicillin/ streptomycin (Invitrogen Inc., Carlsbad, CA). PC3 
cells, called PC3ML2 isolated based on their ability to metastasize to the lumbar 
vertebrae (Wang and Stearns, 1999), were used in some of the experiments. PC3ML2 
cells were maintained in DMEM with 10% fetal bovine serum (FBS) according to 
previously described protocols of ATCC (Amer. Tissue Culture Consortium, Bethesda, 
MD). All the above cell cultures were maintained at 5% CO2 and 37°C.  
Stable over-expression of Ras constructs    
 
Ras mutant constructs were stably overexpressed in both IBC-10a and PCa–20a 
cells using a pBABE-puro retroviral vector (pBABE:RasV12, pBABE:RasV12C40, 
pBABE:RasV12G37 and pBABE:RasV12S35 were kind gifts from Dr. Christian Sell, 
Drexel University College of Medicine). Both retroviral production and maintenance of 
transduced cells was carried out according to methods described by the Nolan lab 
(Wolkowicz, 2004). Briefly, viral particles were isolated from supernatants of transiently 
transfected PhNxA cells. IBC-10a and PCa-20a cells were incubated with retroviral 
supernatants in 10 ug/ml polybrene overnight and stable selection of Ras over expressing 
cells were obtained by culturing cells in the presence of puromycin (5 µg/ml; Sigma-
Aldrich, St Louis, MO) for one week. The empty vector (pBABE-puro-Empty; was a gift 
from Dr. Christian Sell, Drexel University College of Medicine) was used as a control 
(The above transfections were performed by Michael Amatangelo). 
Cell and media treatment with growth factors and EGCG 
 
Primary intermediate basal cells or primary prostate cancer cells (IBC-10a and 
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PCa-20a) were obtained from the stock flask. For the E+T studies, the cells were 
pretreated overnight with Km (minimal media) after which they are treated with EGF 
(10ng/ml), TGFβ1 (10ng/ml) or E+T (EGF and TGFβ1, 10ng/ml each). (EGF and TGFβ1 
concentrations of 5ng/ml and 10ng/ml were used interchangeably due to their similar 
effects on MMP2 and MMP9 production). The cells were treated for 7 or 9 days and the 
media was changed every 3 days over this period. The media was collected from the cells 
after an overnight treatment with fresh media (with or without ligands). For the EGCG 
cell treatment studies, PC3ML2 cell and IBC-10a cells were treated with increasing 
concentrations of EGCG. The IBC-10a cells were treated with E+T for 6 days followed 
by an overnight treatment of EGCG (10uM or 30uM) at 37°C.  The PC3ML2 cells are 
grown in DMEM with 10% Fetal Bovine Serum and are directly treated overnight with 
EGCG (10uM, 30uM, 50uM and 100uM) at 37°C. For the media treatment with EGCG, 
the media from untreated PC3ML2 cells was collected. EGCG at different concentrations 
was added to the media and incubated overnight at 37°C. To identify the effects of 
EGCG on MMP gelatinase activity, zymograms containing MMPs were incubated with 
EGCG overnight. After running the protein samples on the gels, they were incubated 
overnight in separate containers, with and without EGCG at 100uM. After the incubation 
period, the gels were stained using Coomassie blue. 
Protein extraction 
 
 After every experiment, the media from the cells was collected following an 
overnight treatment of the respective experiment. Cell lysis was performed by using 
250ul of lysis buffer (RIPA buffer, 1% protease inhibitor cocktail and 1% Na3VO4). 
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 The collected media were concentrated using Amicon Ultra- 15 centrifugal filter 
devices (Millipore Corp., Bedford, MA). The filters were prewashed with PBS followed 
by centrifugation at 4°C and 5000 rpm for 10 minutes. Alternatively, dialysis bags 
(SpectroPor membrane, MWCO:10,000, Spectrum Labs) were used, where the media 
was dehydrated using and Polyethylene Glycol (molecular weight: 20,000). Both these 
methods resulted in 250- 500ul of protein concentrate. The protein concentration of the 
cell lysates and concentrated media were calculated using the Bradford assay at 595nm. 
A 1mg/ml BSA solution was used as the standard for the assay. A standard curve was 
determined in order to obtain the relative protein concentration of the collected samples.  
Gelatin Zymography 
 
 Gelatin zymography was performed using 10% gels containing Gelatin A 
(2mg/ml). The gels were placed in a gel electrophoresis chamber.1x running buffer (Tris 
HCL, Glycine and SDS) was used as an electrolyte. 0.01-1.5ug of the samples were 
loaded which were mixed with 1x sample buffer. The samples were run at 100V for 
approximately 1.5 hours. The gels were removed from the stacks and placed in the 
incubation buffer (Tris HCl, CaCl2, NaCl, Brij35) for an overnight incubation. The gels 
were stained using 0.2% Coomassie Blue and then destained using the destaining solution 
(25:65:10 of Methanol, Acetic acid and water respectively). They were analyzed and 
imaged using the ChemiDox XRS Gel Documentation system (Bio Rad Laboratories, 
Inc., Hercules, CA)  
Quantification of Zymography data 
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The zymography data was quantified using Image J software. The digested bands 
on the zymogram (image type- TIFF) were selected using the rectangular tool. As 
zymograms are binary images, default Image J settings were used which assumed white 
objects on a black background. [100] The area values obtained from the software for the 
experimental samples were normalized against the negative control group (Km or 
untreated) for all the experiments.  
Statistical Analysis 
 
Results from the first two specific aims were statistically analyzed using one way 
ANOVA comparison (SPSS) of the treated samples (p<0.0256). Each treatment group 
was further compared to the negative control via one sample t- test (SPSS) (p<0.0256). 
The graphs obtained from the quantified data represented the mean + standard deviation. 
The differences between treated groups were analyzed using Tukey post hoc test 
(p<0.0256). The statistical significance of the third specific aim was analyzed using a one 
sample t- test (SPSS). One way ANOVA was not performed on this data as only two 
treated groups were used in this section. Further, the differences between treated groups 
were indicated with an asterix on the graphs. Homogenous subsets are denoted by letters 
(A-C), where groups of one subset are denoted by the same letter.  
Chapter 3. Design component 
Problem identification 
 
Prostate cancer is one of the most common forms of cancer and is a second 
leading cause of cancer death in males. (Carter and Coffey, 2006) Especially affecting the 
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older population, the progressed forms of this disease metastasizes to various organs, 
most commonly to the bone. (Odero-Marah, 2008) The migration of these malignant 
prostate cells to the bone and other areas is poorly understood. The epithelial to 
mesenchymal transition (EMT) is a critical step in converting a benign tumor to a 
malignant one (Polyak and Weinberg, 2009). It has been recently identified that ligand 
binding is one of the ways prostate cancer cells progress into EMT phenotype and TGFβ1 
plays a very important role in this regard (Deckers et al, 2006). This cytokine plays a dual 
role- it is tumor suppressor in the initial stages of cancer but has been found to assist in 
promoting tumor malignancy in the latter stages (Bierie and Moses, 2006). TGFβ1 has 
canonical and non canonical pathways that enable it to induce tumor invasive activities in 
cancers (Zhang et al, 2009). Its cross talk with the EGF has been associated with 
increased invasive capacity in many cancer types (Denys et al, 2008; Odero-Marah et al, 
2008). This study aims to examine the synergistic effect of EGF and TGFβ1 on MMP2 
and MMP9 secretion by primary prostate cancer cells and determine if an intact Ras is 
required for E+T induced EMT in these cells. 
Currently, one primary goal of cancer research is to identify agents that inhibit 
EMT, indirectly blocking metastasis. It was recently observed that green tea drinkers 
have a lower incidence of prostate cancer compared to the rest of the population, 
suggesting anti- cancer effects of green tea ingredients. EGCG is one of the most 
prominent anti oxidants in green tea that contributes to this effect (Fujiki et al, 2002; 
Valcic et al, 1999). This molecule has enormous potential in drug therapies and other 
forms of cancer prevention techniques primarily because of its low toxicity in healthy 
cells. Although androgen deprivation is the main form of therapy in prostate cancers, a 
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few chemotherapeutics that block the EMT exist, like Docetaxel, Prednisone and 
Mitoxantrone. Recent studies have shown that these drugs are more effective when used 
in combination with each other. (Tannock et al, 2004) EGCG can thus potentiate other 
chemotherapeutic agents and increase the efficacy of the treatment with fewer side 
effects. (Stuart and Rhonda, 2008) The combination of raloxifene and EGCG suppresses 
growth and induces apoptosis in MDA-MB-231 cells. Therefore, an added goal of this 
study is to determine if  EGCG can inhibit EGF and TGFβ1 induced EMT in primary 
prostate cancer cell lines. 
Goal 
 
We aim to deduce the specific ligands that can induce EMT via MMP production 
in primary prostate cancer cell lines. An overlapping goal is to examine whether green tea 
extract (EGCG) can inhibit MMP production during EMT. The long term goal of this 
study is to design a therapeutic approach for prostate cancer using EGCG. 
Hypothesis 
 
Growth factors, EGF and TGFβ1, synergistically drive prostate epithelial cancer cells 
towards an EMT phenotype by increasing the MMP2/9 production in them and thus 
increasing their invasive capacity. EGCG has inhibitory effects on MMP production and 
thus blocks EMT in cancer cells. 
Design objectives/ Specific Aims 
 
Aim1: To evaluate the effects of EGF and TGFβ1 on the MMP2 and MMP9 secretion in 
primary prostate cancer cells.  
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Aim2: To determine the importance of an intact Ras signaling pathway for E+T induced 
MMP2 and MMP9 secretion.   
Aim3:
 
 To determine the inhibitory effects of EGCG (green tea extract) on the E+T 
induced MMP secretion in primary prostate cancer cells and in PC3ML2 cells. 
(a) Aim1 
 
To evaluate the effect of EGF and TGFβ1 on the MMP2 and MMP9 secretion in primary 
prostate cancer cells (IBC-10a and PCa-20a).  
(i) Rationale:  
Studies indicate that androgen independent tumors survive and progress with the 
help of growth factors like EGF and TGFβ found in the tumor microenvironment under 
the pressure of androgen deprivation in some patients undergoing hormone ablation 
treatment or other unknown reasons. (Klein et al, 1997) It was initially thought that 
mutations and the presence of oncogenes were necessary for the initiation and 
progression of tumors. Most commonly the H-Ras mutation in prostate cancer has been 
associated with cancer progression, particularly with its conjunctive effort with TGF β1. 
However, more recent studies have shown the presence of growth factors like EGF and 
TGF β1 in the tumor stroma and have been associated with the initiation and progression 
of several steps in these cancers.(Hazelbag et al, 2002) Preliminary results have shown 
that the induction of an EMT phenotype (high Vimentin expression and low E-cadherin 
expression) in human prostate cancer cells co-treated with EGF and TGFβ1. 
(Amatangelo, personnel communication) Our goal is to determine if the combined EGF 
and TGFβ1 treatment can increase MMP2 and MMP9 production in primary prostate 
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cancer cells with the help of gelatin zymography. High MMP2/9 secretion is associated 
with a rise in invasive capacity of cells.  Invasiveness and increased migratory capacity 
are key features of metastatic cells that have undergone EMT and present a mesenchymal 
phenotype. (Liabakk et al, 1996)  
(ii) Specific Aims:  
To observe the effect of TGF β1 and EGF on MMP2/9 secretion in primary 
prostate cancer cells.  
(iii) Experimental Design:  
The media of IBC-10a and PCa-20a cells treated with Km, EGF, TGF β1 and 
E+T was concentrated and the MMP2/9 secretion in the media was measured using 
gelatin zymography. Additionally, the cell morphology of the cells after treatment was 
analyzed using phase contrast microscopy. Figure 6 displays a schematic of the 
experimental design for the first specific aim.  
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Figure 6: Schematic of experimental design for Specific Aim 1.IBC-10a/PC- 20a 
cells were grown in minimal media (Km) overnight before starting growth factor 
treatments. The treatments were maintained for 9 days with change of media every 
3 days. The MMP2/9 secretion in the media collected from the cells was analyzed 
using gelatin zymography. 
(iv) Criteria 
Table 1: Design criteria for Specific Aim 1 
Criterion Rationale 
 
1. Treat cells for 9 days with EGF and 
TGF β1. 
 
Previous experiments have indicated 
that IBC-10a and PCa-20a cells take 
approximately, 9 days to acquire an 
EMT like phenotype. (Unpublished 
data) It was thus necessary to prevent 
highly confluent conditions in the cell 
IBC 10a/20a cells 
grown in Km
IBC 10a/20a cells  
maintained in Km  
for 9 days
Concentration 
of media
Gelatin 
Zymography
Morphology
IBC 10a/20a cells -
EGF treatment 
(5ng/ml) -9 days
Concentration 
of media
Gelatin 
Zymography
Morphology
IBC 10a/20a cells 
- TGF β1 
treatment 
(5ng/ml) -9 days
Concentration 
of  media
Gelatin 
Zymography
Morphology
IBC 10a/20a cells  
EGF (5ng/ml)  and 
TGF β1 (5ng/ml)  
treatment - 9 days
Concentration 
of media
Gelatin 
Zymography
Morphology 
  
34 
plates and the cells were thus seeded at 
less than 25% confluence. 
 
2. The MMP2/9 secretion in the EGF 
+ TGF β1 treated samples should be 
higher than that in control samples 
(Km, EGF alone and TGF β1alone 
samples) 
 
Earlier studies in prostate and other 
organs have shown the EMT phenotype 
being induced with a combined EGF 
and TGF β1 treatment of cells in vitro 
(Denys et al, 2008). Production of 
MMPs are characteristic of an EMT 
phenotype and they assist in increasing 
the migratory and invasive capacity of 
cancer cells. 
 
(v) Constraints:  
The main constraints for the first specific aim are as follows. 
a. The seeding density of the cell dishes needs to be less than 25% in order to 
maintain the cell culture for a period of 9 days.  
b. The treated cells release the MMPs into the media they are grown in and 
therefore the media needs to be used to analyze MMP2/9 secretion of the cells 
(treated and untreated). 
c. The zymography needs to be performed with gelatin as the substrate as MMP2 
and MMP9 are gelatinases.  
d. Pretreatment of the collected media with amino phenyl mercuric acetate 
(APMA) is required to cleave the active band from the pro-enzyme. This step 
could not be performed due to time and monetary constraints. 
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(vi) Alternative solutions: 
The above experiment identifies whether the EGF and TGF combination 
treatment can boost MMP2 and MMP9 levels in primary prostate cancer cells. Another 
area that needs to be analyzed is the regulatory mechanisms that support MMP 
production in these cells. Our results and other current studies have shown that there is a 
difference in the regulatory mechanisms of MMP2 and MMP9 primarily because of 
presence of distinct activators for the two MMPs (Egeblad and Werb, 2002). Therefore 
experiments measuring TIMP2, MMP14 and MMP3 levels post E+T treatment of 
primary prostate cancer cells will be beneficial in identifying the regulatory processes 
behind MMP activation. The levels of TIMPs in the cells can be measured using Western 
blotting or other protein expression assays like Enzyme Linked Immunosorbent Assay 
(ELISA).  
Flourometric analysis is an alternative method to gelatin zymography for 
MMP2/9 secretion measurements. In such an assay, the MMP specific substrate contains 
a flourophore and a light absorbing quencher. These remain attached to an amino acid 
sequence recognized by the MMPs. The enzymatic activity of the MMPs cleaves the light 
absorbing quencher and this step allows the fluorescence to be observed. (Stack et al, 
1989; Knight et al, 1992) The flourometric analysis helps analyze the active MMP2/9 
secretion than measuring the total MMP2/9 secretion as seen in the protocol used in this 
study. However the main downside of using this assay is their low efficiency due to 
optical disturbances from the media and the presence of lipophilic substrates that leads to 
their low solubility in the samples. Beekman et al published a new flourometric protocol 
that used a water soluble flourogenic MMP substrate. Although this protocol increased 
the solubility of the substrate, the water soluble substrate they used was very general ad 
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cannot be used to identify specific MMPs, thus limiting the application of the protocol. 
(Beekman, 1996; Matyoshi et al, 1989)    
(b) Aim2 
 
To determine whether an intact Ras signaling pathway is essential for E+T induced EMT.    
(i) Rationale:  
It is well known that Ras acts downstream of the EGF pathway. Several studies 
have indicated the co-operation between TGF β1 and Ras in promoting an invasive 
phenotype is some cancer types. A study in breast cancer cells was able to show that Ras 
mutation along with TGF β1 treatment was necessary for the induction of an invasive 
phenotype. On further dissecting the Ras pathways using small molecule inhibitors, they 
were able to show that it was the MAPK pathway that TGF β1 cooperated with to induce 
an EMT phenotype which they measured using Vimentin and E-cadherin expression in 
the cells. (Janda et al, 2002)  However, whether this co-operation between TGF β1 and 
the Ras pathway pertains to prostate cancer continues to be debate. The aim of the study 
is to initially identify the existence of the proposed co-operation between the two 
pathways as well as to identify the specific Ras pathway responsible for this interaction. 
(ii) Specific Aims: 
Aim 2a: To evaluate the effects of EGF and TGF β1 on MMP2 and MMP9 
secretion in pBABE V12ras transfected IBC-10a on PCa-20a cells.  
1) Experimental Design:  
The media of pBABE.V12ras.IBC-10a cells treated with Km, EGF and TGF β1 
was concentrated and the MMP2/9 secretion in the media was measured using gelatin 
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zymography. Additionally, the cell morphology of the cells after treatment was analyzed 
using phase contrast microscopy. Figure 7 below displays a schematic of the 
experimental design for the second aim.  
 
 
Figure 7: Schematic of experimental design for Specific Aim 2a. pBABE V12ras IBC-10a 
and pBABE V12ras PCa-20a cells were grown in minimal media (Km) overnight before 
starting growth factor treatments. The treatments were maintained for 9 days with change 
of media every 3 days at a concentration of 5ng/ml of EGF and TGFβ1. The MMP2/9 
secretion in the media collected from the cells was analyzed using gelatin zymography 2) Criteria: 
Table 2: Design criteria for Specific Aim 2a. 
Criterion Rationale 
 
1. The basal levels of MMP2/9 in 
pBABE.V12ras.IBC-10a cells are 
 
Ras transformation has been shown to 
increase the invasive capacity of 
IBC10a/20a Ras 
cells grown in Km
IBC 10a/20a Ras cells  
maintained in Km  for 
7 days
Media 
Concentration
Gelatin 
zymography
Morphology
IBC 10a/20a Ras 
cells  EGF 
treatment- 7 days
Media 
concentration
Gelatin 
zymography
Morphology
IBC 10a/20a Ras cells  
TGF β1 treatment- 7 
days
Media 
concentration
Gelatin 
zymography
Morphology
IBC 10a/20a Ras cells  
EGF and TGF β1 
treatment- 7 days
Media 
concentration
Gelatin 
zymography
Morphology
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more than that in IBC-10a parent 
cells. 
cancer cells by increasing their MMP 
activities. Several studies have shown 
the induction of MMP expression in 
Ras transformed cells via the NF-KB 
pathway which was also able to 
simultaneously decrease the TIMP 
levels in the cells. (Yang et al, 2001). 
The induction of MMPs via Ras 
pathways are also found to be assisted 
with the help of transcription factors 
like AP-1 and Ets-1 (Westermarck et 
al, 2001). 
 
2. The MMP2/9 activities in the 
TGF β1 Ras transformed IBC 
cells is similar to the MMP2/9 
activities of Ras cells treated with 
a combination of EGF and TGF 
β1.  
 
Ras transformed cells have been 
treated with TGF β1 in several cancer 
studies and the results have indicated 
an increase in invasive activity in 
these cells post treatment with this 
growth factor. Several studies have 
directed this co-operation between 
Ras and TGF β1 to the induction of 
the MAPK pathway. (Park et al, 2000; 
Janda et al, 2002) An increase in 
invasive activity in vitro and 
indications of metastasis in vivo 
suggests a possible increase in MMPs 
which generally assists these 
processes. 
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a. The Ras cells in this experiment need to be treated for a period of seven days 
for the cells to attain an EMT phenotype. 
b. The seeding density of the cells on the 10cm dishes should be less than 25% 
to prevent highly confluent conditions. 
c. The media from treated samples needs to be collected on day seven after the 
media is replaced in the dishes on day six to measure the MMP release of the 
cells overnight and not the cumulative MMP released over several days.  
d. The media samples can be analyzed using gelatin zymography to measure 
MMP2 and MMP9 activities as they are gelatinases. 
e. In order to obtain quantifiable images, only 0.05ug of protein could be loaded 
per well. 
f. Effective treatment range for EGF and TGF β1 needs to be between 1ng/ml 
and 10ng/ml.  
g. Pretreatment of the collected media with APMA is required to cleave the 
active band from the pro-enzyme. This step could not be performed due to 
time and monetary constraints. 
4) Alternative solutions: 
Flourometric analysis is an alternative method to gelatin zymography for 
MMP2/9 secretion measurements. In such an assay, the MMP specific substrate contains 
a flourophore and a light absorbing quencher. These remain attached to an amino acid 
sequence recognized by the MMPs. The enzymatic activity of the MMPs cleaves the light 
absorbing quencher and this step allows the fluorescence to be observed. (Stack et al, 
1989; Knight et al, 1992) The flourometric analysis helps analyze the active MMP2/9 
  
40 
secretion than measuring the total MMP2/9 secretion as seen in the protocol used in this 
study. However the main downside of using this assay is their low efficiency due to 
optical disturbances from the media and the presence of lipophilic substrates that leads to 
their low solubility in the samples. Beekman et al published a new flourometric protocol 
that used a water soluble flourogenic MMP substrate. Although this protocol increased 
the solubility of the substrate, the water soluble substrate they used was very general ad 
cannot be used to identify specific MMPs, thus limiting the application of the protocol. 
(Beekman, 1996; Matyoshi et al, 1989)    
As MMPs are indicative of the migratory capacity of the cells, migration and 
invasion assays can be used in Ras cells to compare the migratory capacities with and 
without growth factor treatments. In these methods, the cells to be analyzed are seeded on 
the top chamber of the two chamber assay system which is part of the cell culture inserts. 
After the incubation period the cells migrated into the lower chamber is measured and 
this number is correlated to the migration and invasive capability of the cells. (Brand et 
al, 2005) However this is not a quantitative method to measure MMP activity and 
restricts the analysis to the identification of the number of migrated cells. Additionally, 
this method is more a measure of invasiveness which is indirect measurement of 
MMP2/9 secretion compared to gelatin zymography. 
There are several methods to measure MMP proteins levels in the media. ELISA 
and Western blotting are alternative methods to measure the MMP2/9 production in the 
media quantitatively and qualitatively respectively. But with respect to this study, this 
method has several downfalls too. Like the migration assays, the ELISA and Western 
blotting cannot be used to measure the enzymatic activity of MMPs. These tools can only 
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be used to measure the MMP2/9 protein levels in the media. Thus gelatin zymography 
will be used for the measurement of MMP2/9 secretion. 
Aim2-b: To determine the Ras pathway that cooperates with TGF β1 to increase 
MMP2/9 secretion. 
5) Experimental Design:  
In order to identify the Ras pathway that interacts with TGF β1 to drive cells to an 
invasive phenotype, Ras mutants with specific point mutations at V12, C40, G37 and S35 were 
obtained, which activated the PI3K, RalGDS and MEK pathways respectively. While activating 
the specific pathways, all other Ras pathways get inhibited in these mutant cells. They do so by 
binding preferentially to one effector but failing to bind to the other two. (Rodriguez-Viciana et 
al, 1997) These mutants were treated with TGF β1 (10ng/ml) for 7 days. The media from the 
treated cells was obtained which was analyzed for MMP2/9 secretion using Gelatin zymography. 
Figure 8 displays a schematic representation of the experimental design for Specific Aim 2b. 
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Figure 8: Schematic of experimental design for Specific Aim 2b. pBABE Ras V12 IBC-10a 
and pBABE RasV12 PCa-20a Ras mutant cells were grown in minimal media (Km) 
overnight before starting growth factor treatments. The treatments were maintained for 7 
days with change of media every 3 days. The media collected from the treated cells was used 
for gelatin zymography to analyze MMP gelatinase activities. 
 6) Criteria: 
Table 3: Design Criteria for Specific Aim 2b 
Criterion Rationale 
 
1. The modified Ras cells should 
be able to activate only one Ras 
pathway and disable the other 
pathways. 
 
The RasV12 cells were mutated 
specifically at amino acids C40, G37 
and S35 in order to preferentially 
activate the PI3K, RalGDS and the 
MEK pathways respectively. In order 
to identify the pathway that cooperates 
with TGF β1 in inducing invasive 
properties in Ras cells, it is necessary 
IBC Ras cells 
Ras C40
TGF β1 
treatment 
(10ng/ml)
Media 
concentration
Gelatin 
Zymography
Morphology
Ras G37
TGF β1 
treatment 
(10ng/ml)
Media 
concentration
Gelatin 
Zymography
Morphology
Ras S35
TGF β1 
treatment 
(10ng/ml)
Media 
concentration
Gelatin 
Zymography
Morphology
Ras V12
TGF β1 
treatment 
(10ng/ml)
Media 
concentration
Gelatin 
Zymography
Morphology
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to activate the Ras pathways we are 
interested in analyzing individually 
(Rodriguez-Viciana et al, 1997). In this 
way, only the activated Ras pathway 
possesses the ability to interact with 
TGF β1. The Ras mutant cells that 
show highest MMP2 and MMP9 
activities when compared against other 
Ras mutants will be the one responsible 
for the increased invasive activity in the 
cells as displayed by the MMP2/9 
secretion.  
 
2. The MMP2/9 activities in one of 
the Ras mutants should exceed 
the MMP2/9 activities in the 
other mutants and similar to 
MMP2/9 activities in the normal 
Ras control cells. 
 
The most invasive Ras mutant working 
in conjunction with TGF β1 will be 
expected to produce comparatively 
higher levels of MMP2 and MMP9. 
Earlier studies have shown that Ras 
cells possess a higher invasive potential 
post TGF β1 treatment (Oft et al, 
1996). Therefore, the Ras mutant 
responsible for the invasive phenotype 
of TGF β1 treated Ras cells will be 
measured using MMP2 and MMP9 
activities. 
 
7) Constraints: 
a. The Ras cells in this experiment need to be treated for a period of seven days. 
b. The seeding density of the cells on the 10cm dishes should be less than 25% to 
prevent highly confluent conditions. 
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c. The media from treated samples can needs to be collected on day seven after the 
media is replaced in the dishes on day six to measure the MMP release of the cells 
overnight and not the cumulative MMP released over several days.  
d. The media samples can be analyzed using gelatin zymography to measure MMP2 
and MMP9 activities as they are gelatinases. 
e. In order to obtain quantifiable images, only 0.05ug of protein could be loaded per 
well. 
f. Treatment range for EGF and TGF β1 needs to be between 1ng/ml and 10ng/ml.  
8) Alternative solutions: 
An alternative method to identify the key Ras pathway that cooperate with TGF 
β1 is to use small molecule inhibitors of the Ras pathway namely LY21, LY29 and 
PD098 that have the ability to inhibit the TGF beta pathway, Akt pathway and the MEK 
pathway respectively. These drugs inhibit effectors of Ras and thus inhibit their 
activation. LY29 inhibits PI3K by binding to the ATP- binding site of PI3K enzyme. This 
action usually leads to cell apoptosis in cancer cells induced by blocking the PI3K-Akt 
nexus (Poh and Pervaiz, 2005). The Ras cells that fail to demonstrate a relatively high 
MMP2 and MMP9 activities after the inhibitor treatment along with TGF β1 will direct 
us to the right pathway that is necessary for MMP2 and MMP9 activation, which will 
also suggest the pathway that cooperates with TGF β1 to increase the invasive capacity of 
cancer cells.  
(c) Aim3 
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To determine the effect of EGCG (green tea extract) on MMP2 and MMP9 secretion in 
malignant (PC3ML2) and pre-malignant (IBC-10a, PCa-20a) cell lines. 
(i) Rationale:  
Significant evidence has been provided in the past to support the anti- tumorigenic 
effects of EGCG in rodents as well as in humans through clinical trials. Epidemiological 
studies recently performed have been able to show that this green tea extract had 
significant anti cancer effects in prostate cancer, a result found in several other forms of 
cancer. (Bushman, 1998; Nelson, 2004; Jian et al, 2004; Gupta et al, 2001) Although 
several studies have shown the inhibitory effects of this potential drug in cancer models, 
the mechanism of action of the drug and its effects on MMPs remain unanswered. 
(Shannon et al, 2009) Thus, it is clear that more investigation is required to identify the 
effects of EGCG on the inhibition of prostate cancer metastasis. In this study we aim to 
identify the effects of EGCG on the MMP activities in malignant and pre- malignant 
prostate cell types.  
(ii) Specific Aims 
Aim3a: To identify the concentration of EGCG that can effectively inhibit MMP2/9 in PC3ML2 
and IBC cells. 
1) Rationale:  
The effective concentration of EGCG to inhibit invasive activity in cells varies from one 
study to another and these values change based on the studied cell types. In a prostate 
cancer EGCG study, a concentration of 1uM was able to inhibit cell growth however they 
did not measure MMP2/9 secretion in these cells (Paschka et al, 1998). Another study 
showed the inhibition of MMP2 and MMP9 with EGCG at concentrations ranging 
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between of 0.1nM to 100uM (Garbisa et al, 2001). Therefore it was necessary to identify 
the effective concentration of EGCG in minimizing MMP activities in our prostate cells.    
2) Experimental Design:  
In order to observe the effects of EGCG on PC3ML2 and IBC cells it was necessary to 
identify the dose of EGCG that can effectively inhibit MMP2 /9 in both cell types. 
Therefore, a concentration study was performed on the cells. The primary difference 
between the PC3ML2 cells and the IBC cells is their degrees of malignancies; PC3ML2 
cells are invasive and proliferate at a high rate whereas IBC cells are premalignant and 
less invasive. This difference makes them attain EMT at different rates and conditions. 
PC3ML2 cells do not need an external stimulus to attain an EMT phenotype but the IBC 
cells need to be pre- treated with a combination of EGF and TGF β1 to obtain an EMT 
phenotype. The following diagrams provide a schematic of the experimental designs used 
for each of these cell types. Fig 9 displays the experimental setup for PC3ML2 cells 
(malignant) and the effect of EGCG on these cells was tested using higher concentrations 
of EGCG ranging from 0uM to 100uM. 
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Figure 9: Schematic of experimental design for Specific Aim 3a. PC3ML2 cells were 
grown DMEM with 10% FBS before starting EGCG treatments. The cells were 
treated overnight . The MMP2/9 secretion in the media collected from the cells was 
analyzed using gelatin zymography. 
 
The experimental design for the IBC cells is displayed in the schematic below (Figure 
10). These premalignant cells were treated with EGCG concentrations falling under a smaller 
range between 0uM and 60uM.  
 
 
Figure 10: Schematic of experimental design for Specific Aim 3b. IBC cells were grown E+T 
for 6 days before starting EGCG treatments. The cells were treated with EGCG overnight. 
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The MMP2/9 secretion in the media collected from the cells was analyzed using gelatin 
zymography. 
 
In each case the media of the cells treated with the “drug” was collected, 
concentrated and used for gelatin zymographic analysis.  
3) Criteria: 
Table 4: Design Criteria for Specific Aim 3a 
Criterion Rationale 
 
1. The MMP2 and MMP9 
activities of cells should 
decrease with increasing 
concentrations of EGCG.   
 
The role of EGCG as a drug has not 
been entirely been established till date. 
However, studies in the past have 
shown its inhibitory effects on cancer 
cells including prostate cancer cells. 
(Garbisa et al, 2000) In particular, its 
effects on MMPs have been examined 
where EGCG was found to inhibit 
MMP2 and MMP9 activities (Cheng et 
al, 2003). 
 4) Constraints: 
a. The malignant and premalignant prostate cells need to be treated with cells 
without reaching toxic levels of the drug that causes apoptosis of the cells. 
b. The media of treated cells should be collected before the cells undergo apoptosis. 
c. The EGCG needs to be used within 15-20 minutes after dissolution to prevent 
degradation due to the short half life of the molecule. (Rahman et al, 2006) 
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The Biotrak activity assay system is an alternative to using gelatin zymography 
for measuring the inhibition of gelatinases by EGCG. This method uses microtiter wells 
coated with anti MMP antibodies. The conditioned medium is added to the wells and 
incubated overnight at 4°C. The MMPs are activated using APMA followed by an 
incubation period at 37°C in the presence or absence of EGCG. The intensity of the color 
obtained after the gelatinase digestion is measured at 405nm. However, this method could 
not be used due to lack of access to the Biotrak assay system and budgetary constraints. 
 
Aim3b: To observe the effect of EGCG directly on MMP2/9 by treating the media 
obtained from untreated cells with EGCG. 
6) Rationale:  
Most EGCG studies performed in the past have been unsuccessful in identifying 
the mechanism of action of this molecule and its interaction with MMPs. A few of these 
studies indicate the inhibition of MMP2/9 secretion in these cells via direct binding of 
EGCG to the MMPs leading to its inactivation. Garbisa et al showed that EGCG was able 
to reduce cell proliferation at a concentration of 4uM and 0.08uM which suggests the 
presence of its multiple cellular targets.  It is speculated that the inhibition of MMPs by 
EGCG is due to zinc chelation, but Garbisa and colleagues failed to see this effect in their 
experiments (Garbisa et al, 2001). Several questions about the molecular mechanisms of 
EGCG remain unanswered and treating the media collected from cells with EGCG could 
be potentially used to understand the physical interaction between EGCG and MMPs. 
  
50 7) Experimental Design:  
The media from PC3ML2 cells (malignant cells) were used for the following 
experiments due to the high levels of MMPs produced by these cells compared to the IBC 
cells. EGCG at 40uM and 60uM were added to media in different centrifuge tubes and 
incubated overnight at 37°C. In addition to the above procedure, gels containing MMPs 
were also incubated overnight at 37°C with EGCG to identify the direct effect of EGCG 
on inhibition of MMP gelatinase activity. 
 
 
 
Figure 11: Schematic of experimental design for Specific Aim 3b. Media was 
collected from PC3ML2 cells. This media was treated with EGCG overnight. The 
MMP2/9 secretion in the media collected from the cells was analyzed using gelatin 
zymography. 
 8)  Criteria: 
Table 5: Design Criteria for Specific Aim 3b 
Criterion Rationale 
 
1. The MMP2/9 secretion of the 
media treated with EGCG  
 
 A few studies in the past indicate that 
EGCG can inhibit MMP2/9 secretion 
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should be lower than the 
untreated (control) samples. 
by binding directly to the MMPs and 
deactivating it (Garbisa et al, 2001). 
However this direct binding 
mechanism has not been fully proven 
in prostate cancer cells and therefore 
needs to be further investigated by 
treating media positive for MMPs with 
EGCG.  
 9) Constraints: 
a. The media should be collected from PC3ML2 cells (malignant) or IBC cells that 
are treated with EGF and TGF for at least 7 days (premalignant) to ensure 
adequate basal MMP levels. 
b. The media should be treated with EGCG within the range of 0 and 100uM of 
EGCG to compare results from the cell treatment study. 
c. The EGCG needs to be used within 15-20 minutes after dissolution to prevent 
degradation due to the short half life of the molecule. (Rahman et al, 2006) 
d. The media must be free of cell remnants to ensure that the results are purely 
obtained from the MMPs in the media and not the miscellany present in the cell 
pellets. 
10) Alternative solutions: 
The Biotrak assay system as mentioned earlier (specific aim 3a) could be used to 
detect the change in MMP2/9 secretion in the media before and after EGCG treatments. 
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Chapter 4. Results 
1. The effect of EGF and TGF β1 on MMP2 and MMP9 secretion in primary 
prostate cancer cells 
 
We aimed to observe the effects of TGF β1 and EGF on the MMP2 and MMP9 
activities in primary prostate cancer cells. Preliminary studies were performed to identify 
the optimal EGF and TGFβ1 concentrations for effective induction of MMPs in IBC cells 
(Refer to Appendix A). Accordingly, concentrations between 5ng/ml to 10ng/ml of both 
EGF and TGFβ1 provided desired results. Thus most experiments used either 5ng/ml or 
10ng/ml of EGF and TGFβ1. 
Measurement of MMP2/9 secretion using Gelatin Zymography 
 
IBC-10a and PCa-20a cells (primary prostate cancer cells) were treated with Km 
(minimal media), EGF (5ng/ml), TGF β1 (5ng/ml) and EGF + TGF β1 (E+T) (5ng/ml 
each) for 9 days with a change of media every 3 days. The cells treated with Km were 
used as negative controls in order to detect the basal MMP2/9 levels in them. On day 8 
the cells were given fresh media (with/ without ligands) which was collected on day 9. 
Figures 12a and 12b display the comparative effects of the ligands individually and in 
combination in IBC-10a and PCa-20a parent cells. ProMMP9 (latent form) activity 
increases with individual treatments of EGF and TGF β1 when compared to the negative 
control (cells treated with Km alone). However, there is a dramatic increase in the 
activities of both proMMP9 and the active MMP9 forms in cells treated with both ligands 
(E+T) when compared to rest of the controls (Figure 12).  
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The proMMP2 activity in PCa-20a parent cells followed a trend similar to the 
proMMP9 secretion, although the band intensity was lower in proMMP2 results. As 
expected the Km showed the least amount of activity, followed by EGF treated cells. The 
intensity and band width of proMMP2 bands increased significantly with TGF β1 
treatment and the highest activity was observed in the E+T treatment (Figure 12). 
 In order to attain quantifiable results, it was necessary to obtain thinner bands. A 
loading of 0.01-0.05ug gave rise to quantifiable bands (thinner and distinct); however the 
active MMP9 bands were no more visible.  
 
 
a. b.   
 
Figure 12: Gelatin Zymograms of PCa-20a cells. Above image shows zymograms of samples 
from PCa-20a cells treated with Km, EGF, TGFβ1 and EGF/TGFβ1 (5ng/ml each) for 9 
days. The upper bands in the zymogram show Pro-MMP9 (92kDa) activity and lower bands 
show Pro-MMP2 activity (72kDa). The size and intensity of the bands represents the level of 
gelatinase activity of the MMPs. a. Each well was loaded with 0.05ug of the concentrated 
media collected at the end of the 9 day treatment. The media was changed every 3 days. b. 
Each well was loaded with 1.5ug of the concentrated media collected at the end of the 9 day 
treatment. The media was changed every 3 days. 
 
 
Figure 13: Gelatin zymogram of IBC-10a cells. The above image shows a zymogram of IBC-
10a cells treated with Km, EGF, TGFβ1 and EGF/TGFβ1 (5ng/ml each) for 9 days. Each 
well was loaded with 1.5ug of the concentrated media collected at the end of the 9 day 
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treatment. The media was changed every 3 days. The upper bands in the zymogram show 
proMMP9 (92kDa) activity and lower bands show proMMP2 activity (72kDa). The active 
MMP9 bands are observed immediately below the proMMP bands for TGFβ1 and E+T 
treatments. The size and intensity of the bands represents the level of gelatinase activity of 
the MMPs. 
 
The trend of increasing proMMP9 and proMMP2 activities with E+T treatment 
when compared to individual treatments and Km is maintained in IBC-10a parent cells 
(Figure 13).  However, the active MMP9 bands are noticeable only in cells treated with 
E+T. The proMMP2 band activity in IBC-10a parent cells (Figure 13) increase drastically 
from nil activity in Km treated cells to a very faint band in EGF treated cells. There is a 
boost in MMP2 activity in TGF β1 treated cells when compared to the negative control, 
while maximum activity of proMMP2 is seen in the E+T treatment.  
The graph in figure 14a shows proMMP9 secretion for PCa-20a parent cells 
treated with EGF, TGF β1 and E+T. Similar to the results observed in the zymograms, 
the graph shows maximum proMMP9 secretion in E+T treated samples with a relative 
intensity (RI) of 10 when compared to Km, EGF alone and TGF β1 alone with RIs of 1, 2 
and 5 respectively. The active MMP9 bands could not be quantified with a protein 
loading ranging between 0.01ug and 0.05ug, but could be observed with higher protein 
loading (1ug). However, these gels were difficult to quantify due to the overlapping 
digestion bands among treated samples (Figure13). The quantified proMMP2 results are 
displayed in Figure 14b. The trend of increasing proMMP2 activity with E+T treatment is 
maintained. E+T treatment returned the highest RI of 16.34 when compared to Km, EGF 
and TGF β1 alone with RIs of 1, 3.4 and 11.2 respectively.    
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a.  
b.  
 
Figure 14: The graph comparing the proMMP9 secretion in untreated (Km) and treated 
(EGF, TGFβ1 and E+T) in PCa-20a parent cells. The above graph compares the proMMP9 
secretion in untreated (Km) and treated (EGF, TGFβ1 and E+T) in PCa-20a parent cells. 
Data represents the mean + SD of 3 replicate experiments. The error bars represent the 
standard deviation of the samples. The above activity values were obtained by quantifying 
gelatin zymography data using Image J software. The relative intensity of the treated 
samples was obtained by dividing the intensity value of treated samples by the Km activity 
value. a. proMMP9 secretion in Km samples indicates the basal levels in the PCa-20a 
parent cells. The E+T treated samples have maximum proMMP9 secretion when compared 
to samples treated with EGF and TGFβ1 alone. * indicates a significance (p<0.0256) in one 
way ANOVA with a Tukey post hoc (Groups are different from each other and are 
represented as A,B,C; A=EGF, B=TGF,C=E+T)   b. This graph represents the proMMP2 
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comparison among the treated and control samples. The increasing trend of proMMP2 
activity with E+T treatment is maintained. 
 
Appearance of an EMT phenotype 
 
The IBC-10a and PCa-20a parent cells were treated with 10ng/ml of EGF and TGF 
β1. After seven days of treatment with change of media every three days, phase contrast 
microscopy images were obtained. The E+T treatment induced an EMT phenotype in the 
parent cells as seen in Figure 15. Various morphological changes such as spindle shape 
morphology and lack of cell junctions were evident in the presence of E+T. The cells 
grown in Km were used as the negative control. They displayed cobblestoned 
morphology as expected of epithelial cells along with intact cell junctions. Additionally, 
Western blot analysis of E+T treatments revealed increased Vimentin and Fibronectin 
expression along with reduced E-cadherin and β catenin. Similar results were obtained 
using Immunostaining. (Refer to Appendix C) 
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Figure 15: Gradual induction of an EMT phenotype in IBC-10a and PCa-20a parent cells 
treated with 5ng/ml of E+T. The red arrows in the bottom images indicate the presence of 
elongated, spindle like cells that exhibit a fibroblast like appearance. Cells grown in Km 
were used as the negative control, where they maintained cell junctions and have a 
cobblestone appearance of epithelial cells. 
 
2. Intact Ras signaling required for E+T induced EMT in primary prostate 
cancer cells 
 
Ras is a downstream effector of the EGF pathway and therefore we hypothesize 
that Ras overexpression can eliminate the need of EGF stimulation to assist TGF β1 in 
the induction of EMT and an invasive phenotype in cancer cells (Johnston, 2006). The 
effect of growth factors, EGF and TGFβ1, on the MMP2/9 production in Ras 
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overexpressing primary prostate cancer cells was determined by treating IBC-10a 
RasV12 (Figure 16) and PCa-20a RasV12 cells (Refer to Appendix B) with EGF, TGF 
β1 individually and in combination with each other (E+T) at a concentration of 5ng/ml.  
Measurement of MMP2/9 secretion using Gelatin Zymography 
 
The zymograms are displayed in figure 16 below. Km was used as the negative 
control in the zymograms to observe basal proMMP9 secretion. IBC-10a Ras cells treated 
with EGF alone did not significantly increase proMMP9 activities when compared to the 
TGF β1 alone and E+T treatments. Unlike results observed in parent cells, both TGF β1 
and E+T combination treatment rendered very similar boost in proMMP9 secretion. The 
proMMP2 bands are low in band width and signal intensity for Km and EGF treated 
cells, but there is a drastic increase in this band intensity in cells treated with TGF β1 
alone and with E+T. Similar results were obtained in the PCa-20a Ras cells (Refer to 
Appendix B). The active MMP2 and MMP9 bands are clearly visible only in cells treated 
with TGF β1 and E+T at higher protein loading of 1.5ug/ well (Figure 16b). 
 
a.   b.   
 
Figure 16: Gelatin Zymograms of IBC-10a Ras overexpressing cells treated with Km, EGF, 
TGFβ1 and EGF/TGFβ1. The upper bands in the zymogram show proMMP9 (92kDa) 
activity and lower bands show proMMP2 (72kDa) activity. The size of the bands represents 
the level of gelatinase activity of the MMPs. 5ng/ml of all growth factors were used for nine 
days. a. 0.05ug of protein was loaded per well in this zymogram. ProMMP2/9 activities of 
TGFβ1 and E+T yielded very similar results. The media was changed every 3 days. b. 1.5ug 
of protein was loaded per well in this zymogram. The arrows indicate the presence of active 
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MMP2/9 bands underneath proMMP2/9 bands respectively. ProMMP2 bands in TGFβ1 
and E+T are very similar. 
 
The graphs in figure 17 represent the quantitative analysis of the zymograms 
obtained using the Image J software. The graphical representation of the proMMP9 
digestion data is very similar to the results obtained from zymographic analysis of the 
digestion bands. The TGF β1 and E+T treated samples show the highest proMMP9 
secretion with an RI of 10.4 and 10.6  respectively (also very similar) when compared to 
the Km and EGF alone treated samples with RIs of 1 and 4.4 correspondingly (Figure 
17a).  
ProMMP2 gelatinase activity was very similar to the proMMP9 gelatinase results 
(Figure 17b). It was the highest in TGF β1 and the E+T treated samples, with RIs of 2.85 
and 2.99 respectively compared to 1 and 1.04 of Km and EGF treatments respectively, 
thus showing the similarities in proMMP2 gelatinase activity in TGF β1 and E+T 
treatments.  
a.  
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b.  
 
Figure 17: Graphs comparing the pro-MMP2/9 activities in untreated and treated (EGF, 
TGFβ1 and E+T) pBABE Ras V12 IBC-10a cells The above graphs compare the pro-
MMP2/9 activities in untreated (Km) and treated (EGF, TGFβ1 and E+T) pBABE Ras V12 
IBC-10a cells. Data represents the mean + SD of 3 replicate experiments. The error bars in 
both graphs represent the standard deviation of the samples. The above activity values were 
obtained by quantifying gelatin zymography data using Image J software. The relative 
intensity of the treated samples was obtained by dividing their activity values by the Km 
activity value. a. The graph in this figure shows the increasing trend of RI of proMMP9 in 
pBABE RasV12 IBC-10a cells treated with TGFβ1 and E+T, where both exhibit very 
similar RI. Pro-MMP9 secretion in Km samples indicates the basal levels in the pBABE 
RasV12 IBC-10a cells. * indicates a significance (p<0.0256) in one way ANOVA with a 
Tukey post hoc (Groups are represented as A,B,B; A=EGF, B=TGF,E+T)  b. The graph in 
this figure shows the increasing trend of RI of proMMP2 in pBABERasV12 IBC-10a cells 
treated with TGFβ1 and E+T, where both exhibit very similar RI. Pro-MMP2 activity in 
Km samples indicates the basal levels in the pBABE RasV12 IBC-10a cells. 
 
3. Identification of the Ras pathway that cooperates with TGFβ1 to 
enhance MMP production and activity 
 
The treatment of Ras cells with TGFβ1 when compared to E+T showed that both 
treatments yielded very similar proMMP9 and proMMP2 activities.  These results 
suggest cooperation between one of the Ras pathways and TGFβ1 in order to drive Ras 
cells into an invasive phenotype as exhibited by parent cells treated with EGF and 
TGFβ1.  The Ras mutants C40, G37 and S35 that activate the PI3K, RalGDS and the 
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MEK pathways respectively were treated with TGFβ1 for 7 days and collected after an 
overnight treatment of TGFβ1. Figure 18a compares the proMMP2 and proMMP9 
activities in these Ras mutants treated with TGFβ1with respect to normal Ras cells.  
Measurement of MMP2/9 secretion using Gelatin Zymography 
 
Gelatin zymography revealed that the S35 Ras mutant induced maximum 
proMMP2 and proMMP9 activities when compared to the other Ras mutants. 
Interestingly the proMMP2 and proMMP9 activities in the G37 constructs were lower 
than their activities in normal Ras cells as well as other Ras mutant constructs. This trend 
is more obvious in the zymograms for proMMP9 bands than the proMMP2 bands. The 
proMMP2 activity is also much lower in all Ras mutants compared to the proMMP9 
secretion, evident from the low signal intensity seen in Figure 18a. 
 
a.  b.  
 
Figure 18: Gelatin Zymogram of IBC-10a Ras mutants treated with TGFβ1and E+T. Above 
image shows a zymogram of IBC-10a Ras mutants treated with TGFβ1(10ng/ml) and E+T 
(10ng/ml) at for 7 days. Each well was loaded with 0.01ug of the concentrated media 
collected at the end of the 7 day treatment. The media was changed every 3 days. The upper 
bands in the zymogram show proMMP9 (92kDa) activity and lower bands show proMMP2 
(72kDa) activity. The size of the bands represents the level of gelatinase activity of the 
MMPs.  a. The Ras mutants compared to normal Ras cells include C40 (PI3K activation), 
G37 (RalGDS activation) and S35 (MEK activation). The Ras S35 shows maximum gelatin 
digestion and thus maximum proMMP2/9 secretion compared to the rest of the samples, 
while the Ras G37 shows the least ProMMP9 secretion. b. Gelatin Zymogram of IBC-10a 
Ras mutants comparing E+T (5ng/ml) treatment to the negative control (Km) for 7 days. 
The E+T treatment boosts proMMP9 and proMMP2 activities in all four samples, while the 
Km samples exhibit no MMP2/9 secretion. All the Ras samples showed very similar 
proMMP9 and proMMP2 activities. 
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It was also important to analyze the basal MMP levels in the Ras mutants along 
with the effect of a combined EGF and TGFβ1 treatment on them. The zymogram in 
Figure 18b compares Km and E+T treatment in pBABE RasV12 IBC-10a, pBABE 
RasC40 IBC-10a, pBABE Ras G37 IBC-10a and pBABE RasS35 IBC-10a mutants. 
When grown in Km, all four cell types had no proMMP2 and proMMP9 activities 
whereas the E+T treatment boosted the activities of both proMMPs in all four Ras 
mutants.  
All the Ras mutants were normalized against the pBABE RasV12 IBC-10a cells 
(negative control). It is evident from the graph (Figure 19a) that the Ras S35 mutant 
showed the highest proMMP9 secretion with a RI of 1.07, very similar to that of the 
control cells (RI of 1). The pBABE RasG37 IBC-10a mutants on the other hand showed 
the least amount of proMMP9 secretion with a RI of 0.17. These results recapitulate the 
band intensity analysis used in gelatin zymography. 
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b.  
 
Figure 19: Graphs comparing the proMMP9 and proMMP2 activities in the Ras mutants 
The above graphs compare the proMMP9 and proMMP2 activities in the control pBABE 
RasV12 IBC-10a Ras cells and IBC10a Ras mutants- C40 (PI3K activation), G37 (RalGDS 
Activation) and S35 (MEK activation) treated with TGFβ1. Data represents the mean + SD 
of 3 replicate experiments. The above activity values were obtained by quantifying gelatin 
zymography data using Image J software. The relative intensity of the treated samples was 
obtained by dividing their activity values by the control Ras activity value. a. The relative 
intensities of proMMP9 are compared among the Ras mutants. The RasS35 construct has 
the maximum proMMP9 secretion when compared to other Ras mutants and this value is 
equal to the proMMP9 secretion in the normal Ras cells (Control). Ras G37 construct shows 
the least proMMP9 secretion. * indicates significance (p<0.0256) in a one way ANOVA with 
a Tukey post hoc test. (Groups represented as A,B,C; A= RasC40, B=RasG37, C=RasS35) 
b. The graph compares the proMMP2 activities in normal IBC-10a Ras cells and 10aRas 
mutants, C40 (PI3K activation), G37 (RalGDS Activation) and S35 (MEK activation).There 
is a lack of significant difference in the proMMP2 RI of the Ras mutants.  The trend of 
lower RI in Ras G37 construct compared to other mutants is maintained. Statistical analysis 
performed using one way ANOVA and a Tukey’s post hoc test with a p<0.0256. 
 
The quantified results of the proMMP2 activities in the Ras mutants did not show striking 
differences among the Ras mutants. Although the highest RI of 1.57 was observed in the 
pBABE RasS35 IBC-10a construct, the other mutants displayed similar proMMP2 
activities (Figure 19b) 
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Appearance of an EMT phenotype 
 
After the 7 day treatment with 10ng/ml of E+T, phase contrast images of the Ras 
mutants were obtained (Figure 20). These images help in observing the induction of 
EMT like phenotype in these mutants due to the E+T treatment. The cells in Km 
maintain the epithelial phenotype identified by the cobblestone appearance and the 
clear presence of cell junctions. The E+T treatment induced several EMT 
characteristics noticeable with phase contrast microscopy in the Ras mutants like loss 
of cell junctions and spindle shaped morphology. Similar to the zymogram results, the 
E+T treatment in all four mutants resulted in very similar morphological changes. 
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Figure 20: Comparison of the E+T treatment for in Ras mutants. The above image 
compares the E+T (10ng/ml) treatment for seven days in all four Ras mutants (pBABE 
RasV12 IBC-10a, pBABE RasC40 IBC-10a, pBABE RasG37 IBC-10a and pBABE RasS35 
IBC-10a) with their respective Km controls. It is evident from these images that the E+T 
treatment induces an EMT phenotype, indicated by the fibroblast like appearance along 
with scattering and loss of cell junctions. The Km samples in each of the four mutants 
maintain their epithelial phenotype indicated by their cobblestoned morphology and the 
distinct cell junctions. 
 
4. The inhibitory effects of EGCG on the E+T induced MMP2/9 secretion in 
primary prostate cancer cells and malignant prostate cells 
 
Primary prostate cancer cells and malignant prostate cells were treated with 
EGCG to understand the effect of EGCG on the invasive capacity of cells based on their 
MMP2 and MMP9 production and activity. The media from these cells were collected 
and run on a zymogram to compare their MMP2 and MMP9 gelatinase activity. 
Accordingly, IBC-10a parent cells (pretreated with E+T for 9 days) were treated with 
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10uM, 30uM, 50uM of EGCG and untreated cells were used as the negative control. The 
untreated cells show maximum proMMP9 and proMMP2 gelatinase activities.   
Measurement of MMP2/9 secretion using Gelatin Zymography 
 
As seen in figure 21, the size and the signal intensity of proMMP9 and proMMP2 
bands decrease with increasing EGCG concentrations. The untreated control sample 
exhibits maximum proMMP2/9 activities. Cells treated with 50uM EGCG show least 
proMMP2/9 gelatinase activities. Although 50uM of EGCG is required for a drastic 
decrease in proMMP9 secretion, the proMMP2 band disappears with 10uM EGCG 
treatment. 
 
 
 
Figure 21: Gelatin Zymogram of IBC-10a cells treated with varying concentrations of 
EGCG. IBC-10a cells were treated with varying concentrations of EGCG (0, 10uM, 30uM, 
50uM) overnight. Each well was loaded with 0.05ug of the concentrated media collected at 
the end of the overnight treatment. The upper bands in the zymogram show proMMP9 
(92kDa) activity and lower bands show proMMP2 (72kDa) activity. The size of the bands 
represents the level of gelatinase activity of the MMPs.  The untreated control sample 
exhibits maximum proMMP9/2 activities. The band intensity decreases with increasing 
EGCG concentrations. Cells treated with 50uM EGCG shows least proMMP2/9 activities. 
ProMMP2 band disappears with 10uM EGCG treatment. 
 
The graph in figure 22 shows quantified data of proMMP9 activities in the IBC-
10a parent cells treated with increasing concentrations of EGCG. The decreasing trend in 
the proMMP9 activities with increasing EGCG concentrations correlate with results in 
the zymogram images. As expected, the IBC-10a cells treated with 30uM EGCG has the 
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least relative intensity of 0.04 compared to the untreated sample (RI of 1) and 10uM 
treated sample (RI of 0.21).  
 
 
Figure 22: Graph comparing proMMP9 secretion in untreated and EGCG treated IBC-10a 
cells. The above graph compares the proMMP9 secretion in untreated and EGCG treated 
IBC-10a parent cells. Data represents the mean + SD of 3 replicate experiments. The 
activity values were obtained by quantifying gelatin zymography data using Image J 
software. The relative intensity of the treated samples was calculated by dividing the 
activity value of each experimental sample by the untreated (negative control) activity 
value. The untreated sample shows the maximum proMMP9 secretion and the relative 
intensity values decrease with increasing EGCG concentration. 30uM EGCG shows the 
least proMMP9 secretion among the samples. A trend of decreasing proMMP9 activities 
with increasing EGCG concentration is observed. * indicates significance (p<0.0256) by one 
way ANOVA (Groups are significantly different and represented by A, B; A=10uM and 
B=30uM). 
 
Next, PC3ML2 (malignant) cells were treated with different concentrations of EGCG 
(10uM, 30uM, 60uM and 100uM). Untreated cells were used as the negative control. 
Figure 23a shows a general decrease in proMMP2/9 activities with increasing EGCG 
concentrations suggesting a dose dependent MMP2/9 secretion in the malignant cells, a 
result observed in IBC-10a parent cells. Treatment with 10uM EGCG does not seem to 
affect the MMP2 and MMP9 secretions in PC3ML2 cells, but 30uM EGCG treatment 
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shows a reduction in proMMP2/9 activities as suggested by the decreased band signal 
intensity. 60uM EGCG showed the maximum reduction of the proMMP2/9 activities in 
malignant cells. Figure 23b shows a repetition of the EGCG treatment with 30uM and 
60uM of EGCG which depicted similar trends of decreasing proMMP2 and proMMP9 
activities. 
a.  b.  
 
Figure 23: Gelatin Zymogram of PC3ML2 cells treated with varying concentrations of 
EGCG overnight. The size of the bands represents the level of gelatinase activity of the 
MMPs.  The upper bands in the zymogram show proMMP9 (92kDa) activity and lower 
bands show proMMP2 (72kDa) activity. a. The cells were treated with 10uM, 30uM, 60uM 
and 100uM of EGCG overnight. Each well was loaded with 0.1ug of the concentrated media 
collected at the end of the overnight treatment. The untreated control sample exhibits 
maximum proMMP9/2 activities. The band intensity decreases with increasing EGCG 
concentrations. Cells treated with 50uM EGCG shows least proMMP2/9 activities. b. The 
cells were treated with 40uM, 0uM and 60uM of EGCG overnight. Each well was loaded 
with 0.05ug of the concentrated media collected at the end of the overnight treatment. The 
untreated control sample exhibits maximum proMMP9/2 activities. The band intensity 
decreases with increasing EGCG concentrations. Cells treated with 60uM EGCG shows 
least proMMP2/9 activities. The arrow indicates the presence of an active MMP9 band. 
 
The graphs in figure 24 display these results and they correlate with the trend 
observed in the zymograms. As expected, the PC3ML2 cells treated with 60uM EGCG 
has the least proMMP9 relative intensity of 0.48 compared to the untreated sample (RI of 
1) and 30uM treated sample (RI of 0.6), seen in Figure 24a. Similarly, proMMP2 band 
intensity shows a gradual decline in activity with increasing EGCG concentrations 
(Figure 24b). The 60uM EGCG treatment resulted in least RI of 0.41 compared to the 
untreated sample (RI of 1) and the 40uM treated sample (RI of 0.55).  
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a.  
 
b.  
 
Figure 24: Graphs comparing the proMMP9 and proMMP2 activities in untreated and 
EGCG treated PC3ML2 cells. The above graphs compare the proMMP9 and proMMP2 
activities in untreated and EGCG treated PC3ML2 (malignant) cells. Data represents 
the mean + SD of 3 replicate experiments. The activity values were obtained by 
quantifying gelatin zymography data using Image J software. The relative intensity of 
the treated samples was calculated by dividing the activity value of each experimental 
sample by the untreated (negative control) activity value. a. The untreated sample 
shows the maximum proMMP9 secretion and the relative intensity values decrease with 
increasing EGCG concentration. 60uM EGCG shows the least proMMP9 secretion 
among the samples. b. The untreated sample shows the maximum proMMP2 activity 
and the relative intensity values decrease with increasing EGCG concentration. 60uM 
EGCG shows the least proMMP2 activity among the samples. 
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In order to understand whether EGCG was affecting MMP secretion or inhibiting 
enzymatic activity directly we collected the media from untreated PC3ML2 cells and 
IBC-10a cells and treated it with varying EGCG concentrations. The zymogram in Figure 
25 shows decreasing proMMP2 activity with increasing EGCG concentration in the 
media obtained from IBC-10a cells. However, a significant difference in the proMMP9 
secretion was not observed. 
 
 
Figure 25: Gelatin Zymogram of the EGCG overnight treatment (0, 10uM, 30uM) of media 
obtained from untreated IBC-10a cells. The above image displays a zymogram of an EGCG 
overnight treatment (0, 10uM, 30uM) of media obtained from untreated IBC-10a cells. The 
upper bands in the zymogram show proMMP9 (92kDa) activity and lower bands show 
proMMP2 (72kDa) activity. The size of the bands represents the level of gelatinase activity 
of the MMPs.  Each well was loaded with 0.01ug of the concentrated media collected at the 
end of the overnight treatment. The untreated control sample exhibits maximum proMMP2 
activities, while the proMMP9 bands do not show significant difference in intensities. The 
proMMP2 band intensity decreases with increasing EGCG concentrations. Media treated 
with 30uM EGCG shows least proMMP2 activity. 
The media treatment with EGCG was repeated on media obtained from untreated 
PC3ML2 cells. The media was treated with 0, 40uM and 60uM of EGCG overnight. 
Figure 26 displays the zymogram obtained from the above procedure. A slight decrease 
in the ProMMP2/9 activities was observed with increasing EGCG concentrations. The 
60uM EGCG treatment rendered least ProMMP2/9 activities. However these results were 
not as significant as the effect of EGCG treatment directly on the cells (IBC-10a and 
PC3ML2).  
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Figure 26: Gelatin Zymogram of the EGCG treatment of media obtained from untreated 
PC3ML2 cells. The above image displays a zymogram of the EGCG treatment (0uM, 40uM, 
60uM) of media obtained from untreated PC3ML2 (malignant) cells. Each well was loaded 
with 0.05ug of the concentrated media collected at the end of the overnight treatment. The 
upper bands in the zymogram show proMMP9 (92kDa) activity and lower bands show 
proMMP2 (72kDa) activity. The size of the bands represents the level of gelatinase activity 
of the MMPs.  The untreated control sample exhibits maximum proMMP2/9 activities. The 
proMMP2/9 band intensities decrease with increasing EGCG concentrations. Media treated 
with 60uM EGCG shows least ProMMP2/9 activities. 
 
The graphs in Figure 27 show these quantified results and they display a 
decreasing trend in the proMMP9 and proMMP2 activities with increasing EGCG 
concentrations. Figure 27a shows that the 60uM EGCG treatment results in the least 
proMMP9 secretion with a relative intensity (RI) of 0.72 when compared to the untreated 
sample (RI of 1) and the 40uM EGCG treated sample (RI of 0.88). The quantified 
proMMP2 results are displayed in the graph in Figure 27b. Similar to proMMP9 results, 
the proMMP2 activity RI values show a decreasing trend with increasing EGCG 
concentration. The 40uM EGCG treatment had a higher RI value of 0.87 compared to the 
60uM EGCG treated sample (RI of 0.62).    
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a.  
 
b.  
 
Figure 27: Graphs comparing the proMMP9 and proMMP2 activities in untreated and 
EGCG treated media from untreated PC3ML2 cells Data represents the mean + SD of 3 
replicate experiments. The activity values were obtained by quantifying gelatin zymography 
data using Image J software. The relative intensity of the treated samples was calculated by 
dividing the activity value of each experimental sample by the untreated (negative control) 
activity value. a. The media from untreated cells was treated with 40uM and 60uM of 
EGCG. The untreated sample shows the maximum proMMP9 secretion and the relative 
intensity values decrease with increasing EGCG concentration. 60uM EGCG shows the 
least proMMP9 secretion among the samples.* indicates significance (p<0.0256) in one 
sample t-test (60uM treated group is different from the untreated group). b. ProMMP2 
activities in media from PC3ML2 cells treated with increasing EGCG concentrations of 
40uM and 60uM are represented here. The untreated sample shows highest proMMP2 
activity and there is a decreasing trend in proMMP2 activities with increasing EGCG 
concentrations. 60uM EGCG shows the least proMMP2 activity among the samples. 
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 The lack of significant differences in the proMMP2 and proMMP9 gelatinase activity of 
the media treated with increasing EGCG concentrations led us to analyze the effects of EGCG on 
the gels containing MMPs. The next set of experiments involved the incubation of acrylamide 
gels run with protein samples with 100uM of EGCG. The proteins obtained from media of 
PC3ML2 cells were run on acrylamide gels with gelatin. The gels were then incubated overnight 
in the absence and presence of 100uM EGCG. The Coomassie staining of these gels resulted in 
the zymograms in Figure 28. 
 
 
Figure 28: Gelatin zymogram obtained from incubating gels containing MMP2 and MMP9 
with EGCG at 100uM concentration The zymogram on the right was incubated overnight 
in the presence of EGCG in the incubation buffer. There is no gelatinase activity observed 
in this gel. The figure on the left is the zymogram obtained by running the same proteins as 
run on the gel on the left (same concentrations) but in the absence of EGCG in the 
incubation buffer. In this figure, the proMMP9 and proMMP2 bands are clearly visible at 
92kDa and 72kDa respectively. 
 
Zymograms similar to the ones in figure 28 were obtained each time the experiment was 
repeated confirming the inhibition of gelatinase activity of proMMP2 and proMMP9 by EGCG. 
The lack of bands in the gel incubated with EGCG, made it difficult to quantify the results. 
Chapter 5. Discussion and future work 
 
Local invasion and metastasis are critical steps in cancer progression. One of the 
theories that elucidate the mechanism behind cancer metastasis is EMT- the 
transformation of epithelial cells to a mesenchymal phenotype. This process is 
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characterized by increase in mesenchymal markers like Vimentin, fibronectin and MMPs 
along with a downregulation of epithelial markers like E-cadherin, β catenin and laminin 
(Yang and Weinberg, 2008; Thiery, 2002; Polyak and Weinberg, 2009). The tumor 
microenvironment is a source of several factors that can induce EMT in primary tumors. 
Particularly, tumor associated stroma has been found to be a major source of several 
EMT signals originating from the mesenchyme (Polyak and Weinberg, 2009). Several 
growth factors like TGF, FGF and EGF reside in the stroma and are prospective inducers 
of EMT in cancers (Farrow et al, 2004; Hazelbag, 2002).   
We have examined EMT induction in primary prostate cancer cell lines and for 
the first time have shown that a combination of EGF and TGFβ1 (E+T) can induce EMT 
via secretion of matrix metalloproteinases (MMPs). We have further shown that intact 
Ras signaling is essential for EMT to occur in primary prostate cell lines. We used Ras 
IBC-10a mutants with point mutations at C40, G37 and S35 which activated the PI3K, 
RalGDS and the MEK pathways respectively and inhibited the rest of the Ras pathways. 
The G37 construct inhibits the MEK and the PI3K pathways but activates the RalGDS 
pathway and was able to block MMP production. But a combined EGF and TGFβ1 (E+T) 
treatment of these mutant cells restored MMP production, clearly suggesting that an 
intact Ras pathway with MEK and PI3K activation was necessary for EMT induced 
MMP production in primary prostate cells. One of the primary goals of current cancer 
research is to identify agents that inhibit EMT, indirectly blocking invasion and 
metastasis. We have found that EGCG blocks E+T induced MMP secretion during EMT 
and may, therefore, be an invaluable therapeutic agent for blocking EMT events 
associated with invasion and metastases.  
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High levels of TGF β1 has been found in tumor stroma (Hazelbag et al, 2002) and 
inflammatory responses in cancer leads to the accumulation of EGF in the tissue 
surrounding the tumor (Farrow et al, 2004). Therefore, the combined action of these two 
ligands can induce an invasive phenotype in premalignant cancer cells. MMP2 and 
MMP9 play major roles in determining the invasive capacity of prostate cancer cells and 
are important prognostic markers of prostate cancer (Morgia et al, 2005). When studied 
individually, EGF and TGF β1 treatments have shown significant induction of MMP2 
and MMP9. In ovarian cancer cells, EGF alone was found to induce MMP9 production in 
a PI3K dependent manner (Ellerbroek et al, 2001). The involvement of NF-KB 
downstream of the PI3K pathway has been supported by studies in breast cancer cells 
using NF-KB inhibitors and immunoflourescence results. The authors observed a 
considerable decrease in proMMP9 secretion with an NF-KB inhibitor and this suggests 
the presence of a NF-KB binding site on the MMP9 promoter region (Moulik et al, 2008; 
Le Page et al, 2005) It is well established that TGFβ1 alone can induce EMT in several 
forms of cancer. (Grunert et al, 2003). However, there are several pathways associated 
with TGFβ1 induced EMT. One of them seems to be its interaction with EGF and its 
downstream effectors like Ras.  
It was necessary to identify standard concentrations of EGF and TGFβ1 for all the 
experiments in our studies. Optimal concentrations of EGF and TGFβ1 were identified 
using optimization experiments that used multiple combinations of the two factors on 
primary prostate cancer cells and analyzed their ability to secrete MMPs using gelatin 
zymography. Although, several studies in the past have conducted experiments with 
concentrations varying between 2ng/ml and 10ng/ml, our optimization studies revealed 
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very similar MMP2 and MMP9 gelatinase activities with 5ng/ml and 10ng/ml of EGF 
and TGFβ1 (Refer to Appendix A).   
1. EGF and TGF induce EMT in primary prostate cancer cells: 
The synergistic effects of growth factors, EGF and TGF β1, on the latent and 
active MMP2/9 activities of PCa-20a and IBC-10a parent cells are depicted in Figure 12 
and Figure 13 respectively. The cells treated with Km served as the negative control and 
showed basal proMMP2/9 activities. It is clear from the prominent latent and active 
MMP2/9 activities in the E+T treatments that EGF and TGF β1 work together to enhance 
MMP2 and MMP9 production (Figures 12 and 13).  
 It is evident from figures 12 and 13 that the EGF treatment does not significantly 
induce proMMP2 and proMMP9 activities. On the contrary few studies have shown high 
MMP9 production and activity after EGF treatment of cancer cells (Kuo et al, 2009; Kim 
et al, 2009; Moulik et al, 2008). Although TGFβ1 alone was able to stimulate 
proMMP2/9 activities better than EGF alone, the combined treatment resulted in the 
highest gelatinase activities. Thus, our results indicate that EGF or TGFβ1 alone are not 
able to induce a prominent increase in proMMP2/9 activities and that a combined EGF 
and TGFβ1 treatment is necessary to observe this induction. The graphs comparing EGF, 
TGFβ1 and E+T treatments in primary prostate cancer cells indicate that TGFβ1 has 
more control on proMMP2 and proMMP9 production compared to EGF alone. This 
suggests that E+T as an additive effect on the MMP production in these cells, as the boost 
in the E+T treatment accounts for the sum of the effects of EGF and TGFβ1 on MMP 
production.  
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The lack of active MMP2 and MMP9 bands indicate the absence of MMP 
activators in the media obtained from treated primary prostate cancer cells. This suggests 
the failure of E+T treatment to induce MMP activators like MMP3, TIMP2 and MMP14 
(Egeblad and Werb, 2002).  
In addition to high MMP levels, the E+T treated cells also exhibited several EMT 
characteristics like spindle shaped morphology, loss of cell polarity, Vimentin expression 
and low E-cadherin expression (Refer to Appendix C). These results further indicate that 
E+T treatment induces EMT in primary prostate cancer cells. 
The mechanism of the crosstalk between TGFβ1 and EGF is yet to be dissected. 
Based on the above findings and support from current literature we hypothesize the 
following mechanism of action of TGFβ1 with respect to its role in inducing MMPs 
(Figure 29). Binding of TGFβ1 onto its receptor activates the SMAD anchor for receptor 
activation (SARA) which functions to phosphorylate the SMAD2/3 complex. This step is 
followed by the addition of Cited 2 (CBP/p300- binding transcription co-activator) onto 
the SMAD2/3 complex and this complex enters the nucleus to activate the MMP9 
promoter region. This proposed mechanism explains the upregulation of MMP9 with 
TGFβ1 treatment in the prostate cancer cells used in our study and has been suggested 
based on our experimental results along with data that supports the role of Cited2 in 
activating the MMP9 promoter (Chou et al, 2006).  
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Figure 29: Proposed mechanism of action of TGFβ1 in the induction of MMP9 secretion. 
The activation of TGFβ receptor by TGFβ1 triggers the phosphorylation of SMAD2/3 by 
SARA. This activation step promotes the binding of CITED2 to the SMAD2/3 complex. This 
activated complex enters the nucleus to act upon the MMP9 promoter leading to MMP9 
production and its further secretion. (Idea adapted from Chou et al, 2006) 
 
Past studies have suggested possible mechanisms for MMP2 promoter activation 
via multiple transcription factors in cancer cells initiated by TGFβ1 treatment in cancer 
cells. Several results propose the activation of the MMP2 promoter by ATF2. The 
upregulation of MMP2 is accompanied by increased expression of p38 suggesting the 
activation of the p38/MAPK pathway after cancer cell treatment with TGFβ1. This 
pathway is Smad independent and suggests the role of ATF2 in the activation of MMP2 
promoter. (Kim et al, 2007; Song et al, 2006; Kim et al, 2004) Figure 30 depicts the 
effect of TGFβ1 on the activation of p38 pathway and thus indirectly activating MMP2 
promoter via ATF2 phosphorylation.  
 
TGFβ1 receptor 
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Figure 30: Proposed mechanism by which TGFβ1 activates the MMP2 promoter. Using a 
Smad independent mechanism, activation of the TGFR leads to the activation of the 
p38/MAPK pathway which in turn activates ATF2, a transcription factor found to directly 
bind to the MMP2 promoter region leading to its upregulation. (Adapted and modified 
from Massague, 2000) 
 
2. An intact Ras pathway for E+T induced EMT in primary prostate cancer 
cells: 
Although Ras mutations are not very common among prostate cancers, they are 
indirectly activated by several growth factor receptors that are often activated. Ras 
expression in prostate cancers is also associated with lowered androgen dependency for 
tumor growth, often associated with poor prognosis of prostate cancer. (Carey et al, 2007; 
Gioeli et al, 1999) The Ras Responsive element binding protein (RREB) was recently 
discovered to inhibit androgen receptor regulated transcription in prostate cancer cells. 
However, Ras overexpression in prostate cancer has the ability to inhibit this repressive 
  
80 
activity of RREB and results in increased PSA activity in prostate cancer cells 
(Mukhopadhyay et al, 2007). A recent finding shows that an oncogene- suppressor 
cascade, guided by a RasGAP gene (DAB2IP) promotes prostate tumor growth and 
metastasis. This gene functions as a “signaling scaffold” by regulating Ras and NF-KB. 
(Min et al, 2010) 
It is well established that TGFβ1 is one of the inducers of EMT in cancer. As Ras 
is a downstream effector of EGF, the synergistic effect of EGF and TGFβ1 in increasing 
MMP production indicates a crosstalk between TGFβ1 and Ras signaling pathways.  
Recently, Janda et al was able to show that Ras and TGF β cooperatively induce 
EMT in mammary epithelial cells. Ras transformation of the cells followed by TGF β 
treatment induced spindle shaped morphology, loss of epithelial markers and induction of 
mesenchymal markers. The transformation of these cells into the mesenchymal 
phenotype was permanent as identified by the lack of reversal of mesenchymal phenotype 
when TGF β1 treatment stopped. The study was able to show that only a Ras 
overexpression along with TGF β treatment can induce EMT and that TGF β treatment or 
Ras overexpression alone can only induce “cell scattering”. (Janda et al, 2002)  Similar 
results were seen in Ras transformed hepatocytes with TGF β1 treatment. This study also 
observed growth inhibitory effects of TGF while inducing the conversion of hepatocytes 
to a fibroblastoid phenotype in the presence of activated Ha-Ras. (Gotzmann et al, 2001) 
We observed that TGF β1 and E+T treatments induced very similar boosts in 
proMMP2 and proMMP9 activities in Ras transformed prostate cancer cells (Figure 16). 
The Ras mutation in these cells allows a constitutive expression of Ras and this 
eliminates the need of external activation of the Ras pathway by EGF, which is necessary 
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in parent cells that lack this mutation (as shown by E+T treatments in parent cells). 
Interestingly, the relative intensity of proMMP2 and proMMP9 of TGF β1 in Ras 
transformed cells were similar to the E+T treatments in parent IBC-10a cells. This 
observation suggests that the Ras mutation in the parent cells replaces exogenous EGF 
stimulation of the cells to induce proMMP2 and proMMP9 production.     
Unexpectedly, higher protein loading in Ras cells gave rise to an active MMP2 
band (Figure 16b) and this may indicate the presence of minimal MMP2 activators in Ras 
cells following TGFβ1 and E+T treatment. Current studies exogenously activate the 
proMMPs in the cells by treating them with APMA which cleaves proMMPs to release 
the active form (Ogata et al, 1992; Gum et al, 1997). However, we did not execute this 
step in our studies. We assumed that a general increase in proMMP gelatinase activity 
indicates a proportional rise in their active forms.  
Treatment of Ras transformed cells with TGF β1 indicated a crosstalk between 
TGF β1 and Ras pathways. Further studies with Ras mutants helped dissect the specific 
Ras pathway that cooperated with TGF β1. Ras cells with mutation at C40, G37 and S35 
were obtained which in turn specifically activated the PI3K, RalGDS and MEK pathways 
respectively, while inhibiting the other pathways in each case. Treatment of these mutants 
with TGF β1 showed that the S35 construct exhibited highest proMMP2/9 activities 
compared to the rest of the mutants, followed by the C40 mutant (Figure 17a). This result 
suggests that TGF β1 cooperates with the MEK and the PI3K pathways to induce EMT in 
the Ras transformed prostate cancer cells. Such a result has been seen in prostate cancer 
cells for the first time, although similar data has been shown in other cancers. More 
specifically, the co-operation between Ras/MAPK pathways and TGF β1/ Smad 
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pathways has been implicated in several cancers. Studies in breast cancer cell lines were 
able to show that TGF β1 treatment led to the loss of E-cadherin (marker of EMT) (Janda 
et al, 2002; Oft et al, 2002). Although a clear understanding of this interaction between 
the two pathways has not been achieved, experimental evidence indicate the need for 
both Smad signaling and MAPK for acquiring EMT (Yu et al, 2002; Itoh et al, 2003). A 
Ras mutant study similar to ours was conducted in fibroblasts. Implantation of these Ras 
mutants in mice revealed the critical role of the MEK pathway (RasV12S35) in 
generating metastatic subcutaneous and lung lesions accompanied by increase in ERK1/2 
levels, a result not found in other Ras mutants they used (RasV12C40, RasV12G37) 
(Webb et al, 1998). Although majority of results in this area support MEK activated EMT 
induction and invasion (Bian et al, 2004; Yu et al, 2002), results seem to vary based on 
the cell type. A hepatocyte study that used an immortalized cell line showed the induction 
of a fibroblastoid like morphology in these Ras transformed cells with TGF β1 treatment, 
but also showed that MEK pathway was not involved in this process (Gotzmann et al, 
2002).  
  Surprisingly, the G37 construct (RalGDS activation) in our study inhibited 
proMMP2/9 gelatinase activities signifying the role of the RalGDS pathway in inhibiting 
proMMP secretion. To date no work has been done on the RalGDS pathway that supports 
the above finding. RalGDS is a Ral guanine nucleotide exchange factor (RalGEF) that is 
responsible for the activation of GTPases like Ral. The effective metastasis in several 
cancers (lung, bladders and breast) can be seen upon activating the RalGEFs (like 
RalGDS) and studies show its dependence on the ERK pathway (Wolthius and Bos, 
1999; Gildea et al, 2002). Contrary to this result, studies in breast cancer cell lines show 
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that the Ral pathway along with β arrestin can increase the migratory capacity by 
activating Lysophosphatidic acid (LPA) in breast cancer cells with higher tumorigenecity 
(Li et al, 2009; Li et al, 2008). The above results from the TGFβ1 treatment of the Ras 
mutants led us to investigate the effects of E+T on them. Figure 16b shows that a Km 
versus E+T treatment shows very similar proMMP2/9 activities among Ras mutants. Km 
alone fails to show any gelatinase activity in all four Ras mutants while E+T treatment 
induces proMMP2/9 activities in each cell type. Although the G37 construct seemed to 
inhibit MMP2/9 activation with TGFβ1 treatment, the E+T treatment did not deliver 
similar results. On the contrary it resulted in proMP2/9 activities very similar to the rest 
of the mutants, which implies that the RalGDS pathway does not interact with TGFβ1 to 
induce MMP production and that MEK and PI3K pathways are essential for TGFβ1 
induced MMP production in Ras transformed prostate cancer cells. The G37 construct 
primarily activates the RalGDS pathway while inhibiting the other Ras pathways. The 
presence of EGF may have activated the endogenous Ras in these cells and this effect 
may have superseded the G37 mutation that blocked all Ras pathways except for the 
RalGDS pathway. Apart from directly indicating the pathways that cooperate with 
TGFβ1, the above Ras mutant studies elucidated that the induction of proMMP2 and 
proMMP9 by EGF alone could possibly occur via the MEK and the PI3K pathways.  
3. EGCG inhibits MMP gelatinase activity: 
Although the main focus of our study was to identify the effects of EGF and 
TGFβ1 on MMP2/9 secretion in prostate cancer cells, we were also interested in 
determining ways of counteracting local invasion and cancer metastasis via E+T induced 
MMP2/9 activation studies. One of the natural drugs in the forefront of herbal drug 
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cancer therapies is EGCG- a green tea extract that contains anti-tumorigenic flavanols. 
As an antioxidant, EGCG has been observed to play an important role in tumor 
repression and consequently has been proposed to be used in several cancer treatments. 
(Gupta et al, 2001; Suttie et al, 2003) The low toxicity of EGCG to normal, healthy cells 
and biased apoptotic effects on cancer cells makes it an attractive drug for chemotherapy. 
Due to multiple cellular targets of EGCG, it is difficult to identify a specific mechanism 
of action for this drug on cancer cells. The most commonly reported effects of EGCG in 
biological systems include its antioxidative effects, inhibition of activities related to 
tumor progression, reduction of cell growth, inhibition of cell adhesion to laminin and 
endothelial cells, etc. (Chung et al, 1999; Valcic et al, 1999; Isemura et al, 1993) 
Identifying the cellular pathways this drug particularly interacts with and inhibits is the 
main goal of many current studies. Dong et al was able to show the inhibition of activator 
protein- 1 (AP-1) via inhibition of the JNK pathway in mouse epidermal cells (Dong et 
al, 1997). EGCG was also recently found to prevent phosphorylation of EGFR, Stat3 and 
ERK proteins. As suggested by most EGCG studies, this study on head and neck cancer 
cells also concluded apoptotic activity in EGCG treated cells. (Masuda et al, 2001) Thus, 
multiple effects of EGCG on cancer cells have been recorded till date. 
We conducted a dose response study of EGCG by treating premalignat cells (IBC-
10a) and malignant (PC3ML2) cells with increasing EGCG concentrations. Figures 21 
and 23 show a dose dependent decline in the proMMP2/9 gelatinase activities of cells 
treated with increasing concentrations of EGCG. A minimum concentration of 50uM of 
EGCG was required to dramatically decrease MMP2/9 secretion in PC3ML2 cells, 
whereas lower EGCG concentrations of 10uM and 30uM were enough to drastically 
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reduce proMMP2 and proMMP9 gelatinase activities in the IBC-10a cells. The IBC-10a 
(premalignant) cells were pretreated with E+T for 6 days before the EGCG treatment to 
induce an EMT phenotype in these cells. The PC3ML2 cells on the other hand were 
directly treated with EGCG and were not exposed to E+T treatments as they are highly 
malignant and express EMT characteristics under normal conditions. 
Interestingly, premalignant cells were found to be more sensitive to EGCG 
induced proMMP2 and proMMP9 gelatinase activity. Altering vesicular transport in 
cancer cells is one of the proposed mechanisms for reduced MMP secretion with EGCG 
treatment. (Annabi et al, 2002) It can be hypothesized that malignant cells (PC3ML2) 
have developed better mechanisms to enable MMP transport to the plasma membrane 
along with its secretion. This could explain the need of higher EGCG concentrations to 
reduce proMMP2 and proMMP9 gelatinase activities in PC3ML2 cells, when compared 
to the premalignant (IBC-10a) cells.  
One of the most comprehensive analyses of the effect of EGCG in invasion and 
gelatinase activity in prostate cancer has been done by Garbisa and colleagues. As seen in 
our study, they showed that an overnight cell treatment (neuroblastoma cells) with 
increasing concentrations of EGCG decreased the MMP2/9 activities in these cells. Their 
results indicated a drop in gelatinase activity at a concentration of 5uM although the 
Boyden chamber invasion studies rendered a similar drop in invasive activity at a lower 
range between 0.05uM and 0.15uM. It is surprising that this group obtained MMP 
gelatinase inhibition with EGCG at such low concentrations, even though their method of 
analysis is similar to our study.  
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The Garbisa group also conducted media treatments with EGCG and saw an 
inhibition of gelatinases with increasing EGCG concentrations, a result contrary to our 
data. In order to deduce the mechanism of action of EGCG, the group studied the effect 
of EGCG on gelatin and gelatinases and found EGCG to be preferentially binding to 
gelatinases rather than the substrate itself (gelatin). (Garbisa et al, 2001)  
Apart from its role in inhibiting important pathways associated with EMT, EGCG 
has been found to inhibit MMPs by directly binding to them (Garbisa et al, 2001; Cheng 
et al, 2003). To analyze the effect of EGCG directly on the MMPs we treated the media 
from untreated PC3ML2 cells with increasing concentrations of EGCG at 37°C. 
Interestingly, the media collected from these untreated cells failed to show a drastic 
reduction in their gelatinase activities even with high EGCG concentrations (30uM) 
(Figures 25 and 26). This result was therefore contrary to the that obtained by Garbisa 
and colleagues, who were able to show preferential binding of EGCG to gelatinases at a 
low EGCG concentration of 1uM (Garbisa et al, 2001). It is questionable how this group 
saw such a drastic reduction in gelatinase activity of media treated with EGCG. The 
treatment of the PC3ML2 media with EGCG did not give us significant reduction in the 
gelatinase activity even at high EGCG concentrations of 60uM. Several studies have 
suggested the formation of EGCG- gelatinase complexes. (Cheng et al, 2003; Garbisa et 
al, 2001) However, the presence of SDS in the gels used for zymography may have 
affected the stability of these complexes. To circumvent this issue, we treated the gels 
containing MMPs with and without 100uM of EGCG overnight at 37°C. Contrary to the 
media treatment with EGCG, the gels incubated with EGCG were absolutely clear of any 
gelatinase activity compared to the gel incubated without EGCG, which showed both 
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proMMP2 and proMMP9 gelatinase activities (Figure 28). This result indicated the direct 
inhibition of proMMP2 and proMMP9 gelatinase activities by EGCG.  
It is evident from the results obtained from our EGCG studies as well as those 
found literature that this “drug” uses several mechanisms to inhibit MMP gelatinase 
activity in cancer cells. The cell and gel (containing MMPs) treatments of EGCG suggest 
two possibilities- prevention of secretion of MMPs or direct inactivation of MMPs by 
forming EGCG-gelatinase complexes. Although studies have indicated the role of EGCG 
in transcriptional inactivation of MMPs, our supplementary results showed no change in 
MMP2 protein levels in cells treated with EGCG, eliminating this potential mechanism of 
EGCG in our studies (data not shown).  
The debate on the mechanism of action of EGCG on MMPs continues as several 
studies show contradictory results. In 2004, Vayalil and Katiyar were able to show that 
EGCG inhibits MMP2 and MMP9 expressions in prostate cancer cell lines by repressing 
MAPK pathways which in turn affects the downstream target NF-KB, a factor claimed to 
be responsible for MMP production. The results from this study suggest that EGCG 
inhibits the transcription of the MMPs by deactivating the MAPK pathway, particularly 
by blocking the phosphorylation of ERK1/2 along with p38. (Vayalil and Katiyar, 2004) 
The hypothesis that EGCG prevents MMP secretion is supported by results obtained by 
Annabi and colleagues. Their results suggest that EGCG prevents MMP2 secretion in 
prostate cancer cells and it does so by inhibiting MT-MMP1 dependent MMP2 
activation. (Annabi et al, 2002) We can also speculate that the inhibition of secretion 
could occur due to changes in the membrane organization and the formation of EGCG-
gelatinase complexes. 
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We also observed several morphological changes in the cells treated with EGCG 
apart from its effects on MMP activation. However, after an overnight treatment, cells 
shrank and exhibited cell membranes with serrated edges. Several cells rounded up and 
were found floating in the media. EGCG induced at least 15% apoptosis with an 
overnight EGCG treatment of 30uM in IBC-10a cells, whereas EGCG treatment on 
human fibroblasts (0-50uM) showed lack of apoptosis (Refer to Appendix D). These 
results are similar to Paschka et al that reported apoptotic activity in prostate cancer cell 
lines treated with EGCG (Paschka et al, 1998).  
It is evident from the above results that EGCG can inhibit MMP gelatinase 
activity and can thus be potentially used to block EMT. This can be determined by 
analyzing the expression of Vimentin, E-cadherin and other EMT markers using Western 
blotting along with RT-PCR data to observe changes at the mRNA level of the above 
proteins.  
The stability of EGCG within experimental conditions and after ingestion has 
been well studied. Most studies have indicated the high sensitivity of this flavanol to a 
number of factors most relevant to our study like pH, partial pressure of oxygen and 
temperature. Sang et al have shown that auto-oxidation and epimerization are two main 
routes of EGCG degradation and instability. (Sang et al, 2005) Although our initial 
studies with EGCG gave drastic results clearly suggesting its role in inhibiting MMP2/9 
activities, two months of storage lowered the efficacy of the drug in reducing MMP 
gelatinase activities in cell and media treatments (Figure 23a versus Figure 23b). Noting 
this reduction in its efficiency, we tested higher concentrations of the drug (40uM and 
60uM compared to the 10uM and 30uM) on PCa-20a cells (pretreated with E+T). 
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Increased concentration of EGCG was able to provide results very similar to initial 
studies using lower concentrations (10uM and 30uM). This result indicated the 
degradation and loss of potency of the molecule over time. Low stability levels of this 
molecule may be responsible for this effect as is indicated by several other studies in 
literature. It was reported recently that considerable degradation of EGCG and other 
catechins present in tea occurs over a few months of storage, even in the absence of 
moisture and other obvious environmental factors like pH and temperature changes. This 
study that examined eight different commercial green tea leaves showed that EGCG is 
susceptible to degradation simply by storage within 2 months time. (Friedman et al, 
2009) Thus, it is vital to use EGCG well within a few months in order to examine its 
highest efficacy in cancer treatment.   
Chapter 6. Conclusion 
 
In conclusion, the above results have indicated that firstly an intact Ras pathway 
is necessary for the E+T induced EMT in prostate cancer cells. Specifically, it is the 
activation of MEK and PI3K pathways that bolster the cooperation between the Ras 
pathway and TGFβ1. Additionally, the results from the EGCG studies have shown that 
this molecule has a high potential to be used as an inhibitor of MMPs. Although, the 
mechanisms of actions of this compound is still not clear, our results indicate its role in 
preventing proMMP2 and proMMP9 secretion from cells as well as direct inhibition of 
the gelatinolytic activities of proMMP2 and proMMP9. These results potentiate its role in 
combination drug therapies in prostate cancer.  
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Appendix 
 
Appendix A:  
 
Optimization of EGF and TGFβ1 concentrations that induce EMT in PCa-20a 
cells.  
PCa-20a parent cells were used to represent primary prostate cells for the 
optimization experiments. The cells were treated with various combinations of 
EGF and TGFβ1, as seen in the table below. 
Table 6: Combinations of EGF and TGF β1 for optimization studies 
 EGF TGFβ1 
1. 0ng/ml 0ng/ml 
2. 1ng/ml 1ng/ml 
3. 5ng/ml 5ng/ml 
4. 10ng/ml 10ng/ml 
5. 0.5ng/ml 10ng/ml 
6. 10ng/ml 0.5ng/ml 
7. 1ng/ml 10ng/ml 
8. 10ng/ml 1ng/ml 
 
The cells were treated with the combination of EGF and TGFβ1 for 9 days with a 
change of medium every 3 days. The media from the treated cells were collected 
on the 9th day after an overnight treatment from the 8th day. The media was 
concentrated using Amicon filters (10,000 MW limit). The protein concentration 
was analyzed of this collected media and run on a 10% acrylamide gel containing 
gelatin A (2ng/ml). The results were analyzed when gels were stained using 
Coomassie blue stain. The proMMP2/9 secretion bands of concentrations that 
showed maximum gelatinase activity were regarded as optimum concentration for 
the entire study. 
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a.  b.  
 
Figure 31: Comparison of pro MMP2/9 activities in 20a parent cells at different 
combinations of EGF and TGFβ1 concentrations. The upper bands in the zymogram show 
proMMP9 (92kDa) activity and lower bands show proMMP2 (72kDa) activity. The size of 
the bands represents the level of gelatinase activity of the MMPs.  a. The proMMP2/9 
activities of 5ng/ml and 10ng/ml of both EGF and TGFβ1 are the highest compared and are 
very similar to each other. b. The proMMP2/9 activities are highest in the 10ng/ml EGF and 
TGFβ1 treatment compared to all the other combinations of E+T concentrations. Each well 
of the gel was loaded with 0.05ug of protein in both figures. 
 
The results from the E+T concentration comparison study in PCa-20a 
parent cells can be seen in figure 31. An important observation is the similarity in 
proMMP2/9 activities in cells treated with 5ng/ml and 10ng/ml of both EGF and 
TGFβ1. These concentrations also yielded the highest proMMP2/9 activities 
compared to the 0ng/ml and 1ng/ml concentrations of both ligands. Figure 31b 
shows these results and once again, 10ng/ml of both ligands produced maximum 
proMMP2/9 activities. The combinations of growth factors containing higher 
TGFβ1 concentration resulted in greater proMMP2/9 gelatinase activities 
suggesting the superseding importance of TGFβ1 over EGF in the induction of 
EMT via enhanced MMP activities. These results concur with the findings in the 
literature supporting the positive role of TGFβ1 in EMT induction in cancer cells 
(Lee et al, 2008).  
The PCa-20a parent cells were treated with increasing concentrations of 
EGF and TGF β1 (1ng/ml, 5ng/ml and 10ng/ml) for seven days, with a change of 
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media every three days. Morphological changes in the treated cells were observed 
using phase contrast microscopy images. Increasing concentrations of E+T induce 
an EMT phenotype as seen in Figure 32. Various morphological changes like 
spindle shaped cells and lack of cell-cell junctions were evident with 5ng/ml and 
10ng/ml concentrations of both EGF and TGF β1. 
 
Figure 32: The gradual induction of an EMT phenotype in PCa-20a cells treated with 
increasing concentrations of E+T. The red arrows in the bottom images indicate the 
presence of elongated, spindle like cells that exhibit a fibroblast like appearance. Cells 
grown in Km were used as the negative control, where cells maintained cell junctions and 
have a cobblestone appearance of epithelial cells. 
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Appendix B 
 
The effect of EGF and TGFβ1 on PCa-20a Ras cells 
 
 
 
 
Figure 33: Gelatin Zymogram comparing proMMP2 and proMMP9 activities in 
PCa-20a Ras cells treated with Km, EGF, TGF and E+T for 9 days (all growth 
factors at 5ng/ml). It is evident from the proMMP2 activity results that both TGF 
and E+T treatments induce very similar MMP activities. The higher protein loading 
of 1.5ug enabled observation of the active MMP2 and MMP9 bands. These are 
indicated by black arrows.  
 
Appendix C 
 
Supplementary E+T induced EMT results  
 
 
Figure 34: Western blot analysis of EMT markers in IBC-10a cells treated with Km, EGF, 
TGF and E+T. Tubulin was used as the loading control. Induction of mesenchymal markers 
like Vimentin and Fibronectin is observed with E+T treatment. There is also a simultaneous 
loss of E-cadherin indicative of lost epithelial features in the cells with E+T treatment. 
(Amatangelo, Personnel Communication) 
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Figure 35: Phase contrast microscopy and immunostaining images of IBC-10a cells treated 
with Km, EGF, TGF and E+T (10ng/ml). The phase contrast images show the increase in 
scattering, loss of cell junctions and spindle shaped morphology of cells treated with E+T 
when compared to the Km for 7 days. The loss of β catenin and induction of Vimentin are 
indicative of conversion from epithelial to a mesenchymal phenotype in these cells with E+T 
treatment. Several EMT specific features are minimally seen in TGF alone treatments, but 
they get pronounced with E+T treatment. (Amatangelo, Personnel Communication) 
 
Appendix D 
 
Apoptosis assays in healthy fibroblasts versus prostate cancer cells. 
Apoptosis assays were conducted using Annexin V antibodies via flow cytometry. 
Results (Figure 36) showed that EGCG (0-50 uM) induced significant apoptosis in 
IBC-10a and PC3ML2 cells (Figures 36A and 36b).  Concentrations of EGCG less 
than 20uM induced low levels of apoptosis of less than 5% in both cell types after 2, 
3 and 4 days treatment.  However, higher concentrations of EGCG (at 30uM and 
50uM) induced significant apoptosis of more than 15% and 50% in both IBC-10a and 
PC3ML2 cells, respectively, by 2, 3 and 4 days (Figures. 36a and 36b). On the 
contrary, WI38 fibroblasts treated with similar EGCG concentrations showed that 
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both untreated and EGCG treated cells exhibited low levels of apoptosis (<2%) after 
2, 3 and 4 days (Figure 36C).   
 
a.   b.  
c.  
Figure 36: Comparison of percent apoptosis in IBC-10a, PC3ML2 and fibroblasts. Percent 
Apoptosis in IBC-10a cells. b. Percent apoptosis in PC3ML2 cells .c. Percent apoptosis in 
WI38 fibroblasts. All the above cells were treated with increased dosages of EGCG (0-50 
uM) for 2, 3 and 4 days, respectively. Annexin V (Guava) labeling.  (Stearns et al, in review) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
